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Background. Hyperlipidemia is a common concern in patients with heterozygous familial 
hypercholesterolemia (HeFH) and in cardiac transplant recipients. In both groups, an 
elevated serum LDL cholesterol level accelerates the development of atherosclerotic 
vascular disease and increases the rates of cardiovascular morbidity and mortality. The 
purpose of this study is to assess the pharmacokinetics, efficacy, and safety of cholesterol-
lowering pravastatin in children with HeFH and in pediatric cardiac transplant recipients 
receiving immunosuppressive medication. 
 
Patients and Methods. The pharmacokinetics of pravastatin was studied in 20 HeFH 
children and in 19 pediatric cardiac transplant recipients receiving triple 
immunosuppression. The patients ingested a single 10-mg dose of pravastatin, and 
plasma pravastatin concentrations were measured up to 10/24 hours. The efficacy and 
safety of pravastatin (maximum dose 10 to 60 mg/day and 10 mg/day) up to one to two 
years were studied in 30 patients with HeFH and in 19 cardiac transplant recipients, 
respectively. In a subgroup of 16 HeFH children, serum non-cholesterol sterol ratios (102 x 
mmol/mol of cholesterol), surrogate estimates of cholesterol absorption (cholestanol, 
campesterol, sitosterol), and synthesis (desmosterol and lathosterol) were studied at study 
baseline (on plant stanol esters) and during combination with pravastatin and plant stanol 
esters. In the transplant recipients, the lipoprotein levels and their mass compositions were 
analyzed before and after one year of pravastatin use, and then compared to values 
measured from 21 healthy pediatric controls. The transplant recipients were grouped into 
patients with transplant coronary artery disease (TxCAD) and patients without TxCAD, 
based on annual angiography evaluations before pravastatin.  
 
Results. In the cardiac transplant recipients, the mean area under the plasma 
concentration-time curve of pravastatin [AUC(0-10)], 264.1 ± 192.4 ng.h/mL, was nearly 
ten-fold higher than in the HeFH children (26.6 ± 17.0 ng.h/mL). By 2, 4, 6, 12 and 24 
months of treatment, the LDL cholesterol levels in the HeFH children had respectively 
decreased by 25%, 26%, 29%, 33%, and 32%. In the HeFH group, pravastatin treatment 
increased the markers of cholesterol absorption and decreased those of synthesis. High 
ratios of cholestanol to cholesterol were associated with the poor cholesterol-lowering 




LDL cholesterol by approximately 19%. Compared with the patients without TxCAD, 
patients with TxCAD had significantly lower HDL cholesterol concentrations and higher 
apoB-100/apoA-I ratios at baseline (1.0 ± 0.3 mmol/L vs. 1.4 ± 0.3 mmol/L, P = 0.031; and 
0.7 ± 0.2 vs. 0.5 ± 0.1, P = 0.034) and after one year of pravastatin use (1.0 ± 0.3 mmol/L 
vs. 1.4 ± 0.3 mmol/L, P = 0.013; and 0.6 ± 0.2 vs. 0.4 ± 0.1, P = 0.005). Compared with 
healthy controls, the transplant recipients exhibited elevated serum triglycerides at 
baseline (median 1.3 [range 0.6-3.2] mmol/L vs. 0.7 [0.3-2.4] mmol/L, P=0.0002), which 
negatively correlated with their HDL cholesterol concentration (r = -0.523, P = 0.022). 
Recipients also exhibited higher apoB-100/apoA1 ratios (0.6 ± 0.2 vs. 0.4 ± 0.1, P = 
0.005). In addition, elevated triglyceride levels were still observed after one year of 
pravastatin use (1.3 [0.5-3.5] mmol/L vs. 0.7 [0.3-2.4] mmol/L, P = 0.0004). Clinically 
significant elevations in alanine aminotransferase, creatine kinase, or creatinine ocurred in 
neither group.  
 
Conclusions. Immunosuppressive medication considerably increased the plasma 
pravastatin concentrations. In both patient groups, pravastatin treatment was moderately 
effective, safe, and well tolerated. In the HeFH group, high baseline cholesterol absorption 
seemed to predispose patients to insufficient cholesterol-lowering efficacy of pravastatin. 
In the cardiac transplant recipients, low HDL cholesterol and a high apoB-100/apoA-I ratio 
were associated with development of TxCAD. Even though pravastatin in the transplant 
recipients effectively lowered serum total and LDL cholesterol concentrations, it failed to 
normalize their elevated triglyceride levels and, in some patients, to prevent the 





Familial hypercholesterolemia (FH) is a common genetic disease resulting from 
functionally significant mutations of the LDL receptor gene.1, 2 Consequently, the total and 
LDL cholesterol concentrations of the affected subjects are significantly elevated. High 
serum cholesterol, observable already at birth,3 in a life-long manner, predisposes the 
subjects with HeFH to premature coronary heart disease (CHD). In untreated men, the 
mean age of diagnosed CHD is 48 years,4 whereas untreated women usually develop 
CHD approximately 10 years later.4 In both FH-subjects and non-FH-subjects, numerous 
trials suggest that effective cholesterol-lowering therapy can prevent, delay, and even 
regress the development of CHD.5-15 
 
Accelerated coronary heart disease (TxCAD) is a common and a serious complication in 
both pediatric16 and adult17 cardiac transplant recipients following heart transplantation. 
Various immunological (e.g. rejections), inflammatory (chronic inflammatory response from 
the recipient to the donor endothelial cells), and infectious factors (i.e. cytomegalovirus)18-
21 as well as metabolic factors (i.e. hypercholesterolemia, hypertriglyceridemia and insulin 
resistance)22-30 are thought to predispose transplant recipients to TxCAD.  
 
In adults with HeFH11, 31 and in adult cardiac transplant recipients,32-40 statins, potent 
inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-
limiting enzyme of cholesterol synthesis, have markedly decreased the mortality and 
morbidity of cardiovascular disease. Despite the potential beneficial effects, the lack of 
safety and efficacy data has prevented the use of statins in children until recently. 
Currently, a few statin trials in children with HeFH41-54 and in pediatric cardiac transplant 
recipients55-58 exist, although many of them are limited by the short follow-up time or the 
small number of participants. The purpose of this series of studies is to investigate the 
pharmacokinetics, safety, and efficacy of pravastatin in children with heterozygous FH and 




2. REVIEW OF LITERATURE 
2.1.  Cholesterol and cholesterol metabolism 
2.1.1. Cholesterol 
Cholesterol is an insoluble lipid, which has one hydroxyl group and one double bond in its 
sterol nucleus, and a single side chain consisting of eight carbon atoms. Cholesterol has 
several vital roles; it is, for example, an essential component of cell membranes and 
lipoproteins, and a precursor for bile acids, adrenal steroids (hydrocortisone and 
aldosterone) and sex hormones (estrogens and androgens), and vitamin D metabolites, 
and is an important factor in neural myelinization and brain growth.59 
 
Humans obtain cholesterol from diet (exogenous pathway) and from de novo synthesis 
within the body (endogenous pathway) (Figure 1). 
2.1.2. Cholesterol transport  
Due to their lipophilic nature, cholesterol and triglycerides are transported in blood by 
lipoproteins classified by increasing density as chylomicrons: chylomicron remnants, very-
low-density lipoproteins (VLDL), low-density lipoproteins (LDL), intermediate-density 
lipoproteins (IDL), and high-density lipoproteins (HDL) (Figure 1).60 The basic composition 
of the lipoproteins is similar, consisting of a core of cholesteryl esters and triglycerides 
surrounded by a surface coat of phospholipids, unesterified cholesterol, and apoproteins. 
The quantities and qualities of apoproteins vary in the particles: Apolipoprotein B (apoB) is 
the chief apolipoprotein of LDL, VLDL, and IDL, whereas apolipoprotein As, which can be 
subdivided into apolipoprotein A-I (apoA-I) and apolipoprotein A-II (apoA-II), are the main 








Figure 1. Exogenous and endogenous pathways of cholesterol metabolism and mechanisms of cholesterol 
transport. B-100, apolipoprotein B100; B-48, apolipoprotein B48; C, apolipoprotein C; E, apolipoprotein E; 
CETP, cholesteryl ester protein; LPL, lipoprotein lipase. Small solid and open circles represent the LDL 




2.1.3. Exogenous pathway 
The exogenous pathway of lipids originates from the intestine.61 In adults, the daily 
amounts of dietary and biliary cholesterol vary between 250 - 500 mg and 600 - 1000 mg, 
respectively. Approximately half of this cholesterol is absorbed in the small intestine and 
half is excreted in stools. Exogenous fats are packed into chylomicrons, which are 
transported via lymphatic vessels into the circulation.60 Lipoprotein lipase (LPL), located at 
the surface of the vascular endothelium of the adipose and muscle tissue, hydrolyzes most 
of the triglycerides into free fatty acids.60 The resulting particles, referred as to chylomicron 
remnants, are then cleared from the circulation by the liver.62 
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2.1.4. Endogenous pathway  
The endogenous lipid pathway originates from the liver.63-65 The liver secretes cholesterol 
into the circulation in triglyceride-rich VLDL particles, which can then be transformed into 
IDL in a process where by LPL most core triglycerides are removed, and some surface 
molecules are lost to HDL.60 The IDL particles can be either removed from the circulation 
by the hepatic LDL receptors,63 or further converted into LDL particles by lipolysis of the 
core triglycerides.60, 64 LDL is an essential lipoprotein particle, which carries cholesterol to 
the peripheral cells. 
 
Cells are capable of taking up cholesterol from lipoproteins that contain apolipoprotein 
B100 (apoB-100) (LDL, partially catabolised VLDL, IDL). ApoB-100 is a surface protein 
that binds to the LDL-receptor.60 The majority of LDL-receptors are located at the 
parenchyma of hepatocytes. The lipoprotein particles bound the receptor are taken into the 
cell by endocytosis,66, 67 after which the receptor and its ligand dissociate and the receptor 
is recycled back to the cell surface. In most cells, the cholesterol released from LDL 
particles down-regulates the synthesis of new LDL receptors, and thus inhibits the cellular 
accumulation of cholesterol.  
 
Even though the liver is generally considered the primary organ for newly synthesized 
cholesterol, all dividing human cells are capable of synthesizing cholesterol.68 Cholesterol 
is synthesized within the cells in peroxisomes and in the endoplasmic reticulum (ER). 
Figure 2 shows a simplified presentation of cholesterol synthesis: an early stage in 
cholesterol synthesis is the conversion of acetyl-CoA via two enzymatic steps to HMG-
CoA, which is then converted to mevalonate.69-71 The 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase is the rate-limiting enzyme of this irreversible step, and 
the activity of the enzyme is down-regulated by cholesterol. Newly synthesized cholesterol 
can be utilized by the liver, stored in the liver in an esterified form, excreted into bile, or 
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2.1.5. Elimination of cholesterol 
Except for the small portion of cholesterol that is lost from the body as steroid hormones or 
through the renewal of skin and hair, elimination of excess cholesterol occurs in the liver 
through excretion via bile as an unaltered cholesterol molecule or as cholesterol 
incorporated into bile acids.68, 72, 73 Cholesterol and bile acids continuously cycle between 
the intestine and the liver in a process known as enterohepatic circulation. Approximately 





2.1.6. Regulation of cholesterol metabolism  
The serum LDL cholesterol concentration is modified by the degree of hepatic cholesterol 
synthesis, cholesterol uptake from the blood by LDL-receptors, cholesterol elimination via 
bile, and cholesterol (both biliary and dietary cholesterol) absorption in the intestine. 
Overall, the absorption and synthesis of cholesterol are tightly linked to maintain 
cholesterol homeostasis; and, in general, as absorption increases, synthesis decreases, 
and vice versa.73-75  
 
2.1.7. HDL particles and reverse cholesterol transport 
Approximately one third of serum cholesterol is carried in the HDL particles. HDL particles 
participate in the reverse cholesterol transport process: they remove free cholesterol from 
peripheral tissues and transport it to the liver.60, 76, 77 HDL particles also have antioxidant 
and anti-inflammatory properties78, 79 that prevent the oxidation of LDL particles.60 The 
anti-inflammatory effects of HDL have been shown to occur at endothelial level, where 
HDL particles decrease the action of cytokine-mediated adhesion molecules.80-82 HDL also 
seems to protect the endothelial cells from cytotoxic damage caused by remnants of 
triglyceride-enriched lipoproteins,83 and to trigger the proliferation of endothelial cells in the 
repair process.78 
 
2.2. Heterozygous familial hypercholesterolemia 
2.2.1. Pathogenesis 
Familial hypercholesterolemia (FH) is an autosomal co-dominantly inherited disease 
resulting from mutations of the LDL receptor.1, 2, 84 The LDL receptor gene is located on the 
short arm of chromosome 19, and its mutations can lead to abnormalities in receptor 
synthesis or transport, the LDL-binding capacity of the receptor, the internalization of LDL, 
or the recycling of the receptor back to the cell surface.85 In heterozygous FH (HeFH), the 
affected individual inherits an LDL receptor gene with a functionally significant mutation 
from one parent, resulting in an approximately 50% reduction in the number of functional 
LDL receptors.86 In its homozygous form, both genes are defective, leaving all of the LDL 
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receptors defective. Altogether over 900 different mutations of the LDL-encoding gene 
have been identified word-wide (www.ucl.ac.uk/fh/). In Finland, seven different mutations 
of the LDL receptor gene (FH-Helsinki [large deletion], FH-North Karelia [small deletion], 
FH-Turku [G823D], FH-Pori [L380H], FH-Pogosta [ R574Q], FH-Fin11 [ D558N], and FH-
Fin12 [ C331W]) are responsible for approximately 93% of all FH cases 
(www.ucl.ac.uk/fh/).87-90 In the Caucasian population, HeFH affects approximately one in 
500 individuals,86 and is thus one of the most commonly known single-gene-determined 
disorders in man. Homozygous FH (not further discussed in this review) is rare, affecting 
only approximately one in a million individuals. 
 
The impaired LDL receptor function leads to an accumulation of LDL cholesterol in the 
blood due to the defective hepatic uptake. An additional elevation in serum LDL 
cholesterol levels results as the cellular uptake of other lipoproteins containing the apo 
B100 (i.e. VLDL, IDL) (Figure 1) is also delayed, and these precursor lipoproteins are 
consequently catabolized into LDLs.1  
 
2.2.2. Symptoms and signs 
High serum cholesterol in subjects with HeFH can already be detected at birth,3 and 
hypercholesterolemia is often the first sign of the disease.91 A distinctive difference in 
cholesterol levels between children with HeFH and healthy subjects develops during the 
first year of life,3 and this difference remains unchanged until adulthood. In children, HeFH 
is the most common cause for marked hypercholesterolemia,92 but the distribution of 
cholesterol concentrations may overlap with those of the general population. Over the 
course of a lifetime, high cholesterol strongly predisposes the untreated subjects with 
HeFH to premature CHD.93-95 Men with untreated HeFH may develop symptomatic CHD 
as early as in their thirties, and the cumulative probability of CHD increases markedly with 
age: 20% by 40 years of age, 45% by 50, and 75% by 60.96, 97 Mortality among untreated 
men is 23% by 50 years. 96, 97 Untreated women with HeFH usually develop CHD 
approximately 10 to 15 years later than men do, and by ages 50 and 60, the cumulative 
incidence of CHD is approximately 20% and 32%, respectively.95-97  
 
Early signs of atherosclerosis, such as fatty streaks, carotid artery plaques,98 increased 
carotid artery intima-media thickness,98-102 endothelial dysfunction103 and decreased 
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carotid-artery elasticity,101, 104, 105 can already be detected in some patients by ages 3 to19 
years. Tendon xanthomas, which usually occur in the Achilles, patellar, and extensor 
tendons of the hand, are also pathognomonic to FH, and often appear in the second 
decade of life.106, 107 Most individuals affected by HeFH develop xanthomas at some point: 
Kwiterovich et al. reported xanthomas based on clinical examination by an experienced 
clinician in 3% of patients aged 1-9 years, in 13% of patients aged 10-19 years, in 70% of 
patients aged 20-29 years, and in 90% of patients aged 30-39 years.106 Based on 
ultrasonography examinations, researches have reported an even higher incidence of 
xanthomas.108 The detection of tendon xanthomas is clinically relevant, since a recent 
study by Civeira et al. showed that tendon xanthomas are associated with higher CHD 
risk.109 The authors suggested that patients with xanthomas may require more aggressive 
lipid-lowering therapy. Other clinical manifestations of hypercholesterolemia include 
corneal arcus and xanthelasma, of which the former occurs in approximately 50% of HeFH 
patients over 30 years of age.86 Despite these early clear clinical signs, the diagnosis of 
HeFH is unfortunately often missed until symptomatic vascular disease develops, which 
will likely worsen the prognosis. 
 
2.2.3. Diagnosis 
In adults, HeFH constitutes only a small portion of hypercholesterolemia, whereby it is 
difficult to differentiate between HeFH and other forms of hypercholesterolemia based 
solely on increased cholesterol levels. A clinical diagnosis is more reliable if other factors, 
such as the presence of tendon xanthomas and personal or family history of premature 
CHD, are also considered. For eligibility of the lower special reimbursement for statins, the 
Social Insurance Institution of Finland (KELA) defines FH in children by the following 
criteria (www.kela.fi/in/internet/suomi.nsf/alias/laake211):  
1. Main criteria (the patient must meet both criteria):  
A) Serum total cholesterol concentration is > 8 mmol/L, despite dietary intervention.  
B) Secondary causes of hypercholesterolemia and hypercholesterolemia caused by 
hypertriglyceridemia have been excluded.  
2. Additional criteria (the patient must meet ≥ 1 criteria):  
A) At least one first degree relative has verified FH. 
 B) The patient has tendon xanthomas 
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C) At least one first degree relative has developed CHD at an exceptionally young age 
(men under 45 years of age and women under 55 years of age). 
 
HeFH can also be verified by DNA analysis of the underlying molecular defect in the LDL 
receptor gene. 110  DNA analysis is convenient in regions such as Finland, where only a 
few mutations are responsible for the majority of the HeFH cases. 87-90 In some other 
regions, however, the notable mutational heterogeneity in the LDL receptor gene may limit 
its use in routine diagnosis. Another option is to conduct an in vitro functional assay to 
measure the binding, internalization, and degradation of 125I-labeled LDL by cultured skin 
fibroblasts,111 or to measure the ability of freshly-isolated lymphocytes to proliferate when 
cultured in a lipoprotein-deficient medium in the presence of mevinolin, an inhibitor of 
endogenous cholesterol synthesis.112 
 
2.2.4. Psycosocial aspects of early diagnosed HeFH 
A study by de Jongh et al. showed that 44% of HeFH children emotionally suffered from 
the disease, and that 38% of the parents considered HeFH to be a burden on their 
family.113 However, 62% of the HeFH children said that pharmaceutical treatment of 
hypercholesterolemia made them feel safer. 113 Several studies have shown that the 
psychosocial cabability of children with HeFH is similar to that of the general age-matched 
population. 113-115 The emotional impact of the premature death of an affected parent is, on 
the other hand, very significant,116 and is associated with poor school performance and 
increased expression of anger.113 
 
2.3. Accelerated coronary artery disease of the heart transplant (TxCAD) 
2.3.1. Patient survival and accelerated coronary artery disease 
Since 1967, when the first human heart transplantation was carried out, both technical 
procedures and immunosuppressive medication have developed considerably, leading to 
substantial improvement in the graft and patient survival.  However, as reported by the 
International Society of Heart and Lung Transplantation (ISHLT) which maintains a registry 
of annual transplantation data from over 80 centers in the USA and Europe, long-term 
survival after cardiac transplantation in both adult17 and pediatric16 cardiac transplant 
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recipients remains rather poor (Figure 3 A ). As Figure 3 B shows, accelerated coronary 
artery disease of the heart transplant (TxCAD) is an important cause of poor long-term 
graft survival. According to a recent ISHLT report, the incidence of angiographic detectable 
TxCAD seven years after transplantation in adult cardiac transplant recipients is 45.7%, 
and in pediatric recipients, 15.2% (Table 1).16, 17 Because qualitative coronary angiography 
underestimates the severity of the coronary disease, even more patients would exhibit 
intimal thickening if examined by the intravascular ultrasound (IVUS) method.117-119 
 
Various immunological (rejections),20  inflammatory (chronic inflammatory response from 
the recipient to the donor endothelial cells),21 and infectious factors (cytomegalovirus, 
Chlamydia pneumonie, enterovirus infection etc)18, 19 are thought to predispose transplant 
recipients to TxCAD. Also, metabolic abnormalities, such as hypercholesterolemia,27 
hypertriglyceridemia,23, 26, 28, 30, 120 increased body mass index,22, 25 and glucose 
intolerance,24, 28, 29 are frequently observed in transplant recipients, and are considered 
significant risk factors for TxCAD. However, TxCAD can also appear in the absence of any 
known risk factors. Hypercholesterolemia frequently manifests after cardiac 
transplantation,58, 121, 122 and is often aggravated by the use of cyclosporine.123, 124 In both 
adult28 and pediatric125 cardiac transplant recipients, the use of corticosteroids can lead to 
a metabolic abnormality characterized by a combination of high triglycerides together with 
insulin resistance and low HDL cholesterol.24, 28, 29 In Finland, the main 
immunosuppressive therapy in pediatric recipients consists of cyclosporine, azathioprine, 
and methyl prednisone, while tacrolimus and mycophenolate mofetil (MMF) serve as 
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Figure 3. Panel A shows the patient survival of pediatric patients following heart transplantation. Panel B 
shows the graft survival after diagnosis of coronary artery vasculopathy in pediatric patients. The data by the 






Table 1. The prevalence of TxCAD and some known cardiovascular risk factors  
in adult and pediatric cardiac transplant recipients following heart transplantation. 
   
The ISHLT registry data.   
    
 1 y after Tx 3 y after Tx 7 y after Tx 
    
Adults n = 9659 n = 6221 n = 2103 
Pediatric  n =2184 n =696 n = 357 
    
TxCAD     
Adults 8.7% 32.3% 45.7% 
Pediatric 2.5% 11.0% 15.2% 
    
Hypertension    
Adult  72.6% 94.0% 97.7% 
Pediatric  46.7% 61.4% 65.8% 
    
Renal dysfunction    
Adult 25.7% 32.4% 35.6% 
Pediatric 5.8% 9.4% 11.4% 
    
Hyperlipidemia    
Adults 49.8% 85.1% 91.2% 
Pediatric 10.1% 21.4% 26.3% 
    
Diabetes    
Adults 23.7% 33.2% 36.5% 
Pediatric 3.2% 4.6% 3.9% 
    
Data in percentages    
Reference: Taylor et al. 2005;17 Boucek et al. 200516 





2.4.1. Typical atherosclerosis vs. transplant vasculopathy 
Figure 4 illustrates the variant characteristics of typical atherosclerosis and allograft 
vasculopathy. Typical atherosclerosis shows characteristic focal, eccentric, proximal 
thickenings of the inner portion of the artery wall in association with fatty deposits (see also 
chapter Pathophysiology of atherosclerosis below).126 It usually affects the large and 
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medium-sized arteries such as the aorta, and the iliac, femoral, coronary, and cerebral 
arteries.127 The internal elastic lamina is typically disrupted, and calcium deposits are 
frequently present.126 The development of typical atherosclerotic lesions may take years. 
The early signs of atherosclerosis appear in the arterial intima during childhood and 
adolescence. 103, 104, 128-135 In fact, some have been found in stillborn and newborn 
babies.136, 137 The early development of atherosclerosis can be greatly enhanced by 
maternal hypercholesterolemia.136 In the presence of risk factors, this process then 
continues throughout life. High serum total and LDL cholesterol, low HDL cholesterol, high 
blood pressure, poor glucose intolerance, cigarette smoking, and obesity, are known risk 
factors for atherosclerosis in adults, but have also been shown to correlate with the 
development of atherosclerotic changes in children.130, 133-135, 138 Without lipid-lowering 
therapy, serum cholesterol measured at 22 years of age seems to predict the risk of 
coronary heart disease (CHD) over the next 30 to 40 years among the general 
population.139 Autopsy studies, such as Pathobiological Determinants of Atherosclerosis in 
Youth and the Bogalusa Heart Study, indicate that early signs of atherosclerosis in 
adolescents are common.128, 135 In autopsy studies, the extent of both fatty streaks and 
fibrous plaque have been shown to correlate with non-HDL cholesterol levels (determined 
post-mortem).140 Furthermore, atherosclerotic plaques seem to develop later in the same 
regions in which the early atherosclerotic changes occur. 127, 133 
  
The pathological processes in transplant vasculopathy, in turn, favor concentric, occlusive 
distal, diffuse coronary changes rather than conventional atheroma-like lesions (Figure 
4).141 In typical transplant vasculopathy, the internal elastic lamina is usually intact, calcium 
deposits are absent, and signs of vasculitis occur infrequently. The development of 
transplant vasculopathy is expected to take months, rather than years, as in typical 
atherosclerosis.126 Histological studies suggest, however, that transplant vasculopathy has 
a spectrum of pathologic features, and that lipid deposits and calcification may also appear 
later on in the older cardiac allografts.142 This is not surprising, since both adult and 
pediatric cardiac transplant recipients also commonly have a high incidence of the 
traditional risk factors for cardiovascular diseases, such as hypertension, hyperlipidemia, 
renal dysfunction, and altered glucose metabolism (Table 1) (ISHLT registry data).16, 17 
Thus, in addition to changes in the endothelium and smooth muscle cells, the 







Figure 4.  Characteristics of typical atherosclerosis and transplant vasculopathy. Adapted with permission 
2006 from Avery.141 . Copyright © 2003 Massachusetts Medical Society. All rights reserved. 
 
 
2.4.2. Pathophysiology of atherosclerosis  
The development of atherosclerosis is a complex process in which several factors and 
processes play a role.143 Local injury and the increased permeability of the intima enhance 
the entrapment of LDL particles and VLDL remnants in the arterial wall, which is usually 
considered the first step in atherosclerosis. Macrophages engulf modified LDL from the 
arterial walls through scavenger receptors. In contrast to the LDL receptor-mediated 
pathway, in which the cholesterol released from LDL particles down-regulates the 
synthesis of new LDL receptors, the scavenger receptors are not similarly down-regulated. 
Hence, macrophages continue to take up cholesterol regardless of its intracellular 
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accumulation. This leads to the formation of foam cells, which contain large droplets of 
cholesterol ester. Foam cells are distinctive to atherosclerosis: the accumulation of foam 
cells and intercellular lipid in the intima of arteries leads to the formation of fatty streaks, 
which may then be further converted into fibrous plaques and finally into complicated 
atherosclerotic lesions. 144 Even though a plaque itself restricts the blood flow by narrowing 
the vessel lumen, it does not typically cause clinical symptoms (e.g. chest pain) until the 
degree of stenosis reaches approximately 70% or greater.145 However, even smaller 
plaques can cause myocardial infarction by rupturing, because the resulting thrombus may 
completely occlude the vessel lumen and cease the blood flow from downstream.  
 
Factors contributing to increased infiltration of lipoproteins into the arterial wall, decreased 
cholesterol transport away from arterial wall, increased endothelial permeability or 
vulnerability, or enhanced thrombosis can promote the development of atherosclerosis.146, 
147 Large experimental, epidemiological, and clinical studies have demonstrated that high 
LDL cholesterol and low HDL cholesterol are independent risk factors for atherosclerosis, 
both of which enhance the accumulation of cholesterol in the arterial wall.148-152 In the 
context of metabolic syndrome, hypertriglyceridemia and altered glucose metabolism lead 
to the enrichment of HDL particles with triglycerides, and consequently, these triglyceride-
enriched HDL particles function as a good substrate for hepatic lipase. Hepatic lipase 
hydrolyzes HDL triglycerides (also phospholipids), causing a formation of small apoA-I 
enriched particles that are prone to catabolism via the kidney function.153, 154 This cascade 
leads to an overall reduction in levels of circulating HDL cholesterol. Besides the traditional 
risk-factors, infectious, inflammatory and immunological factors are also known to play a 
role in the pathogenesis of atherosclerosis; and inflammatory cells (i.e. T-cells), 
macrophages and mast cells, have been found in atherosclerotic lesions.146, 155-161 In fact, 
both the metabolic risk-factors (i.e. high triglyceride levels, persistent glucose intolerance, 
and other abnormalities associated with metabolic syndrome), as well as a variety of 
immunological and inflammatory factors, have been shown to predict the development of 




2.5. Treatment of hypercholesterolemia 
 
2.5.1. Non-pharmaceutical therapy of hypercholesterolemia 
The U.S. National Cholesterol Education Program (NCEP) guidelines163, 164 and the 
Finnish national Current Care guidelines165 (Käypä hoito, published in August 2004; 
www.kaypahoito.fi) primarily recommend dietary intervention and physical exercise for the 
treatment of hypercholesterolemia. Table 2 summarizes the effects of non-pharmaceutical 
interventions on serum lipids and lipoproteins as well as on cardiovascular mortality. The 
U.S. NCEP guidelines propose that if a diet (American Heart Association Step 1 diet) that 
restricts the daily amount of saturated fat to < 10% of total calories, total fat to < 30%, and 
cholesterol to < 300 mg, is insufficient, a diet (Step 2 diet) that restricts total fat to 15% of 
total calories is recommendable. In general, dietary therapy lowers the serum total 
cholesterol by 3 to 6%.165-167 Stricter interventions that reduce the daily fat content from 35 
- 40% of energy to 15 - 20% of energy further reduce serum total cholesterol, with a total 
reduction of approximately 10 - 20%.168, 169 Besides cholesterol-lowering therapy, the 
elimination of other risk factors for cardiovascular disease, such as obesity, smoking, high 
blood pressure, and physical inactivity, is also considered important.163-165, 170  
 
Plant sterols and stanols are structurally related to cholesterol, but cannot be synthesized 
in humans, and therefore originate from the diet (i.e. nuts, vegetable oils, seeds, cereals, 
and beans). Plant sterols and stanols are nowadays incorporated into some food products 
because of their cholesterol-lowering effects. The daily intake of 2.0 – 2.5 g of plant sterols 
or plant stanols reduces the serum levels of total and LDL cholesterol by approximately 
10%.171-174 Although the underlining mechanism is not fully understood, it seems that plant 
sterols and stanols decrease cholesterol absorption by displacing cholesterol from mixed 













Table 2. Effects of non-pharmaceutical interventions on the levels of serum lipids and lipoproteins, and on 
overall cardiovascular morbidity. 
 
Intervention         Lipids           Morbidity 
 
Reducing          Total cholesterol         Decreases 
dietary fat intake      decreases by 3 – 6%   
 
Suplementation of plant     Total cholesterol        Effects unknown 
sitosterols or sitostanols    decreases by 6 – 10% 
 
Increasing dietary       Total cholesterol         Decreases 
fiber intake        decreases by 5 – 6% 
 
Physical exercise     HDL cholesterol increases by 5%     Effects unknown 
  
           Triglycerides decrease by 4% 
          LDL cholesterol decreases by 5% 
 




2.5.2. Pharmaceutical treatment of hypercholesterolemia 
Aggressive drug therapy is often required to normalize the serum cholesterol levels in 
HeFH. According to the Finnish national Current Care guidelines (Käypä hoito), the target 
total and LDL cholesterol concentrations among the general population are defined as < 
5.0 mmol/l and < 3.0 mmol/l, but for high risk patients (i.e. subjects with HeFH), the targets 
are set even lower (4.5 mmol/ and 2.5 mmol/l, respectively).165 Several types of drugs are 
available for the treatment of HeFH: Bile acids binding agents (or ion exchange resins) (i.e. 
colestipol and colestyramine) bind to bile acids in the small intestine, and prevent their 
reabsorption in the enterohepatic circulation, and thus decrease the endogenous 
cholesterol stores as new bile acids form in the liver with cholesterol as their precursor. 
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Bile acid binding agents lower serum cholesterol 10 to 15%.178-181 Fibric acid derivatives 
(i.e. gemfibrozil, clofibrate, bezafibrate and fenofibrate) substantially decrease serum 
triglycerides and moderately increase HDL cholesterol concentrations, but only modestly 
(approximately 5 to 15%) lower total and LDL concentrations.182, 183 Until recently, the 
underlining mechanisms for fibric acid derivatives remained unclear, but recent studies 
have shown, that they increase lipoprotein lipase-mediated lipolysis and alter the 
transcription of proteins that control lipoprotein metabolism.184 Statins (e.g. simvastatin, 
lovastatin, pravastatin, fluvastatin, atrovastatin and rosuvastatin) inhibit 3-hydroxy-3-
methyl-glutaryl-coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme of cholesterol 
synthesis, and decrease serum LDL cholesterol by 30-70%.185 Ezetimibe is a selective 
inhibitor of cholesterol absorption186 that decreases serum total cholesterol by 20%.187 In 
clinical practice in adults, ezetimibe is also often combined with a small statin dose, 
yielding a total reduction of serum cholesterol of approximately 60%. 187 
 
2.5.3. Treatment of hypercholesterolemia in childhood and adolescence  
The Finnish national Current Care guidelines (Käypä hoito) and the U.S. NCEP guidelines 
recommend dietary therapy as the primary cholesterol-lowering treatment for children with 
HeFH.163-165 The benefits of dietary therapy in healthy children have been documented as 
early as during the first year of life.188-190 Large, randomized controlled trials up to seven 
years of duration assessing the efficacy and safety of cholesterol-lowering diets in 
hypercholesterolemic children have been promising, suggesting no adverse effects from 
moderate fat restriction in young children, assuming that caloric intake is adequate.191, 192 
In children, plant stanols or sterols also safely lower serum total and LDL cholesterol levels 
by approximately 6-10% and 9-19%, respectively.193-196 Due to high baseline levels in 
HeFH, dietary interventions are, however, seldom sufficient to normalize serum cholesterol 
concentrations, and drug therapy is often required. 
 
Due to the many crucial roles of cholesterol in growth, brain myelinization, and pubertal 
development, cholesterol-lowering drug therapy in children has raised concerns.197 At 
present, the Finnish national Current Care guidelines (Käypä hoito) recommend that if total 
and LDL cholesterol concentrations remain significantly elevated (> 7 mmol/l and > 5.5 
mmol/l), the child or adolescent should be remitted to a pediatrician specialized in the 
treatment of dyslipidemias.165 The guidelines also emphasize that target cholesterol levels 
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should be determined individually taking into account the patient’s family history of CHD. 
Bile acid binding agents such as colestipol and colestyramine are recommended as the 
primary choice of drug therapy for hypercholesterolemic children; the guidelines state that 
the use of statins in children requires special consideration due to limited long-term safety 
data. The U.S. NCEP similarly recommends bile acid sequestrants for children > 10 years 
of age with insufficient dietary response.163, 164 However, bile acid sequestrants are 
generally insufficient in children with HeFH due to the sequestrants’ modest efficacy, 
unpleasant side-effects, and poor compliance.180, 181, 198 While the long-term safety of 
resins is generally accepted, niacin has been avoided in the treatment of children because 
of serious side-effects, such as hepatotoxicity. The European Commission and the U.S. 
Food and Drug Administration (FDA) have currently approved pravastatin for the treatment 
of such HeFH-children over eight years of age, whose LDL cholesterol levels remain 
elevated after adequate dietary therapy. In addition, the U.S. FDA has approved 
atorvastatin for pediatric use by in children over ten years of age. 
 
Several studies in children with HeFH and a few retrospective studies in pediatric cardiac 
transplant recipients addressing the short-term safety and tolerability of statins are 
available nowadays (Table 3).41, 43-58, 199 Until recently, the long-term safety of statins in 
children remained poorly understood. However, recent studies of the growth and 






Table 3. Studies with statins in children and adolescents with heterozygous familial hypercholesterolemia (HeFH) and in 






















HeFH patients        
Pravastatin        
Knipscheer et al.41 
(1996) 




18 54 5-10-20 8-16 12 23-33 





 36 10 + 
colestipol 
5 g 
9-18** 18 17 





108 106 20-40 8-18 104 24 
Simvastatin        






16 47 20 8-17 6 31-38 
Dirisamer et al.48 
(2003) 
uncontrolled  20 5-10-20 10-17 52 25-36 
Ducobu et al.49 
(1992) 
uncontrolled  32 (male) 10-20-40 <17 104 37 






69 106 10-20-40 10-17 48 31-41 
Stefanutti et al.53 
(1999) 
uncontrolled 8 8 10 4-12 52 29 
Lovastatin        




with a four-week 
placebo period 
 69 (male) 10-20-30-
40 
13† 8 21-36 
Sinzinger et al.52 
(1992) 
─  9 20 6-13 208 28 
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65 (male) 67 (male) 10-20-40 10-17 48 17-27 










20-40 11-18 24 23-27 
Atorvastatin        
Athyros et al.44 
(2000) 
uncontrolled  16 (male) 10-20-40 10-17 156 45 





47 140 10-20 10-17 26 40 
 
Pediatric cardiac transplant recipients 
Pravastatin        
Penson MG et al.57 
(2001)  
uncontrolled**  22 10 to 20 10-21 56 29 
Mahle et al.56  
(2005) 
uncontrolled**  22 0.1-0.3 
mg/kg 
NA 52 15*** 
Seipelt et al.58  
(2004) 
uncontrolled**  20 5-20 0.1-16 26 34 
Atorvastatin        
Chin et al.55 
(2002) 
uncontrolled**  23-38 0.2 ± 0.1 
mg/kg 
12† 19 24-39 
* Combination therapy of pravastatin and colestipol in patients with familial hypercholesterolemia or with familial combined 





2.6.1.  Background 
Statins reduce hepatic cholesterol synthesis by inhibiting the rate-limiting enzyme of cholesterol 
synthesis, HMG-CoA reductase (Figure 2).69, 200 As a consequence of reduced cholesterol synthesis, 
hepatocytes increase the number of LDL receptors on their cell surface in order to meet cholesterol 
demands.200 This leads to a reduction in serum total and LDL cholesterol concentrations. The first 
drug of this class, mevastatin (also known as ML-236B and compactin), was isolated as a fungal 
metabolite from cultures of penicillium citrinum.201, 202 Other early statins (lovastatin, pravastatin, and 
simvastatin) that, unlike mevastatin, are still in clinical use, are also modified fungal extracts, whereas 
the newer statins, fluvastatin, atorvastatin, pitavastatin (currently in clinical use in Japan), and 
rosuvastatin, are synthetic compounds.185, 203-205 Pravastatin and rosuvastatin are the most 
hydrophilic statins, whereas simvastatin and lovastatin are the most lipophilic. 185, 203-205 
 
The metabolism of various statins differ considerably (Table 4).185, 203-207 The active compounds are 
acids derived from the hydrolysis of precursor drugs. Statins have several metabolic pathways. 
Rosuvastatin is glucuronidated for excretion, while simvastatin, lovastatin, and atrovastatin are 
metabolized by cytochrome P450 (CYP) 3A4.205 Fluvastatin is metabolized by CYP 2C9.203 
Pravastatin is cleared via both renal and non-renal routes, and its systemic elimination does not use 
CYP3A4 oxidation to any great extent, but rather uses multiple other oxidative and conjugative 
pathways.208 
 
Pharmacokinetic interactions of statins, with for example cyclosporine, itraconazole, and macrolide 
antibiotics, have been reported206, 209-212 to lead to markedly increased plasma concentrations of 
statins213, 214 and to severe side-effects, such as muscle toxicity.215-217 Because cyclosporine inhibits 
CYP 3A4,218 drug transporters such as P-glycoprotein,219 intestinal efflux transporter MRP2,220 and 
liver-specific uptake transporters OATP1B1,221, 222 interactions with statins have been hypothesized 
to result from the competitive inhibitory effects of cyclosporine on drug catabolism or from the 
inhibition of statin transport. Unlike many other statins, pravastatin is unsusceptible to CYP-mediated 
drug interactions and is only a weak substrate of P-glycoprotein.208, 211, 223, 224 However, cyclosporine 










































































































































































































































































































































































































































































2.6.2. Adverse effects of statin monotherapy  
Statins are generally safe and well-tolerated:227-230 The most common clinical side-effects 
include gastrointestinal symptoms (i.e. nausea, flatulence, diarrhea, and constipation), 
headache, and muscle pain. Elevated liver transaminases or muscle enzymes occur in 
0.5-2.0% and 0.08-0.09% of users, respectively.230 Rhabdomyolysis is a rare, but 
potentially dangerous, side-effect.216, 217, 231, 232 Statins must enter cells to exert their 
action, and the uptake of hydrophilic pravastatin, for example, requires an active 
transportation system. Therefore, differences in uptake may in theory explain some of the 
tissue-specific side-effects of both drugs and individuals. However, the overall tolerability 
of statin monotherapy is generally good with no clinically significant differences in the 
safety profiles of different statins.233 
 
2.6.3. Lipid- and lipoprotein-modifying effects of statins  
The cholesterol-lowering efficacy of statins varies considerably (Figure 5). Pravastatin and 
fluvastatin are the weakest statins, yielding a maximum LDL reduction of ~ 30% at top 
dosage (40 and 80 mg, respectively).185, 234 Lovastatin, simvastatin, atorvastatin, and 
rosuvastatin reduce LDL cholesterol levels dose-dependently by a maximum of 30-70%. 
185, 187, 233-236 Doubling the statin dose generally results in an additional 5 – 7% reduction in 
LDL cholesterol concentrations.229, 234 Because triglyceride-carrying lipoproteins (IDL, 
VLDL) are also transported into hepatocytes via the LDL receptor, statins lower the level of 
serum triglycerides to some degree.185  The effects of statins on HDL cholesterol are 
poorly understood and are somewhat drug specific: pravastatin, lovastatin, fluvastatin, 
simvastatin and rosuvastatin increase HDL cholesterol by a maximum of ~ 4 – 10%, 
whereas a low dosage of atorvastatin increases HDL cholesterol, but a high dosage 




Figure 5. The LDL cholesterol-lowering efficacy of pravastatin, simvastatin, atorvastatin and rosuvastatin in 
increasing doses. Figure modified from Schuster.234 
 
2.6.4. Effects of statins on atherosclerosis and CHD  
Numerous studies have proven that, in the primary and secondary prevention of CHD in 
high-risk patients with and without hypercholesterolemia, effective cholesterol-lowering 
therapy with statins decreases the risk of acute coronary events.6, 7, 9, 10, 12, 237-239 A recent 
meta-analyses by Law et al. indicated that the lower the serum cholesterol levels with 
statins, the lower the risk of cardiovascular events.240 Statin therapy has been shown to 
stabilize endothelial inflammation and atherosclerotic plaques and to decrease serum C 
reactive protein levels.241-245 In a study by Smilde et al., the thickness of the intima-media 
in the carotid arteries of adults with HeFH was reduced by 0.031 mm over a two-year 
period with 80 mg atorvastatin, but was increased by 0.036 mm with 40 mg simvastatin.11 
Nolting et al., however, reported a reduction of 0.081 mm in the thickness of the intima-
media in the carotid arteries with two years of 80 mg simvastatin.8 Furthermore, Wiegman 
et al. and de Jong et al. have recently demonstrated that, respectively, pravastatin can 
reduce intima-media thickness and restore the endothelial function in children with 















































2.6.5. Statins in the treatment of cardiac transplant recipients 
In adult cardiac transplant recipients, pravastatin and simvastatin therapy has markedly 
decreased blood cholesterol concentrations, rejection rates, and overall cardiovascular 
morbidity and mortality, thereby improving patient and graft survival.32-40 Additional studies 
are, however, still warranted, since other trials on kidney transplant recipients have 
reported no effects of statins on the rejection rates.247, 248 Besides their cholesterol-
lowering effects, some researchers believe that statins also benefit transplant recipients by 
exerting a variety of immunosuppressive and immunomodulatory effects.21, 249-251 
Cholesterol-reductions can also benefit cardiac transplant recipients in several additional 
ways. The reduction of lipoproteins may increase in the biological activity of cyclosporine 
by increasing the fraction of unbound cyclosporine. Furthermore, as hypercholesterolemia 
seems to provoke lipid peroxidation, cause oxidative stress, increase the activation of 
resting T-cells and endothelial cells, and increase the secretion of various cytokines, 
chemokines and growth factors by macrophages, reduction of cholesterol may hinder 
these inflammatory pathways.21 Recent studies suggest, however, that statins would also 
exhibit cholesterol-independent effects. Kwak et al. reported in an in vitro study that statins 
also act as repressors of major histocompatibility complex class II (MHC-II) expression.252 
Weitz-Schmidt et al. discovered that statins prevent the costimulation of T-cells by 
selectively blocking the leukocyte function antigen-1 (LFA-1).253 Katznelson et al. showed 
that pravastatin acts synergistically with cyclosporine to inhibit vascular smooth muscle 
mitogenesis and to reduce cytotoxic T-lymphocyte activity.254, 255 In many centers, statins 
are nowadays used in routine post-transplantation therapy. Several major trials have 
yielded promising results concerning the safety and cholesterol-lowering efficacy of statin 
therapy in cardiac transplant recipients.37, 38, 55, 57, 121, 232, 256-260 In pediatric and adolescent 
transplant recipients, however, the safety data on statins are limited, and only a few 
retrospective studies have been published (Table 3).55-58 Careful follow-up of transplant 
recipients receiving statins and cyclosporine is important, since their co-administration is 
known to lead to increased plasma concentrations of statins213, 214 as well as to serious 





In adults, about 34% of the oral dose of pravastatin is absorbed.203, 261 The overall 
bioavailability of pravastatin averages 18%, since about 50% of the absorbed drug is 
subject to pre-systemic hepatic metabolism.261 Pan et al. have shown, that the 
bioavailability of pravastatin dropped markedly when the drug was taken with a meal. 262 
Hence, in pharmacokinetic studies, it is important to evaluate the fasting concentrations of 
pravastatin. However, because reductions in total and LDL cholesterol were equal in the 
fasting and non-fasting groups, in clinical practice  pravastatin can be administered 
regardless of meal time.262 
 
The major metabolites of pravastatin, 3-α-iso-pravastatin, 6-epi-pravastatin, 3α,5β-
dihydroxy-pravastatin and 3-hydroxypravastatin,263  are almost inactive.203 Unlike with 
many other statins, CYP enzymes do not significantly biotransform pravastatin,208 and it 
thus is not susceptible to CYP3A4-,211 CYP2C9-224 or CYP2C19-mediated224 drug 
interactions. Pravastatin is cleared via both renal and nonrenal routes, (47% and 53%, 
respectively), and the half-life in adults is 1 to 3 hours.261, 263, 264 
 
Pravastatin is a substrate of at least canalicular multispecific organic anion transporter 
(cMOAT or MRP2)225, 226 but not that of P-glycoprotein.265 Pravastatin is also transported 
by members of the OATP-family.221, 222 OATP1B1 is responsible for the hepatic uptake of 
pravastatin.266, 267 OATP2B1 transports pravastatin from the gut lumen to the cytosol of 
intestinal epithelial cells and may facilitate its absorption there,268 while MRP2 transports 
absorbed pravastatin back to the gut lumen and also mediates the biliary excretion of 
pravastatin from hepatocytes.265 Organic anion transporter 3 (OAT3), a member of the 
SLC22 superfamily, may affect the urinary excretion of pravastatin.269 
 
 38
3. AIMS OF THE STUDY 
 
The aim of this dissertation was to study pharmacokinetics, efficacy, and safety of 
pravastatin therapy in children. 
  
The specific subjects included were (Table 5a): 
 
The pharmacokinetics of pravastatin in children with HeFH and in pediatric cardiac 
transplant recipients. 
• To assess the pharmacokinetic profile of pravastatin in children with HeFH 
and in pediatric cardiac transplant recipients receiving triple 
immunosuppressive medication 
•  To determine, whether pravastatin pharmacokinetics differ between children 
and adults by comparing the results of this study to those of previous studies 
in adults.  
• To assess the effects of immunosuppressive medication on pravastatin 
pharmacokinetics by comparing the HeFH children (receiving no concomitant 
drug therapy) to the cardiac transplant recipients 
 
The efficacy of pravastatin in children with HeFH and in pediatric cardiac transplant 
recipients 
• To determine the lipid- and lipoprotein-modifying efficacy of pravastatin in 
children with HeFH and in pediatric cardiac transplant recipients 
• To investigate the effects of pravastatin therapy on non-cholesterol sterols in 
children with HeFH, and to investigate whether differences in cholesterol 
absorption and synthesis, assayed with serum non-cholesterol sterols, could 
explain differences in responsiveness to pravastatin. 
• To investigate whether lipid and lipoprotein levels or lipoprotein compositions 
differ between pediatric cardiac transplant recipients and healthy pediatric 
controls  
• To investigate, whether lipid or lipoprotein levels or lipoprotein composition 
differ between the transplant recipients who show signs of TxCAD and those 




The safety of pravastatin in children with HeFH and in pediatric cardiac transplant 
recipients 
• To evaluate the potential clinical side-effects of pravastatin, and to assess 
adverse effects of pravastatin on liver, kidney, and muscle cells in children 
with HeFH and in pediatric cardiac transplant recipients 
• To assess the effects of pravastatin on growth, pubertal development, and 




4.1.  Children with HeFH   
 
Consecutive patients admitted to the Hospital for Children and Adolescents, Helsinki 
University Central Hospital, due to hypercholesterolemia were considered candidates for 
an open, clinical follow-up study of pravastatin treatment. According to the normal clinical 
protocol of the Hospital for Children and Adolescents, during the first visit, the 
hypercholesterolemic children were clinically examined, their family history was reviewed, 
and their cholesterol levels were evaluated. In addition, a dietician reviewed their diets. 
With the consent of the patients and their families, FH was diagnosed by LDL receptor 
mutation analysis90 or by the lymphocyte test.112 If patients tested negative for the four 
most common LDL receptor mutations in Finland, detection of familial 
hypercholesterolemia was carried out by assaying low-density-lipoprotein receptors on 
lymphocytes. The patients then visited the hospital again after two months of dietary 
intervention consisting of a low-fat (energy from fat < 30% of total energy), reduced 
saturated fat (< 10% of total energy), and low cholesterol (< 100 mg/day) diet, with 
supplementation of plant stanol or sterol esters (2.0 g/d). Those patients with genetically-
verified HeFH who were at least four years of age, who had serum total cholesterol ≥ 6 
mmol/L regardless of the dietary intervention, and who, together with their families, 
volunteered for the study and accepted the study protocol, were enrolled without selection. 
Figure 6 illustrates the study protocol and the examinations performed at each visit. 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The goals of this series of studies are described in Table 5a. Figure 7 illustrates the HeFH 
patients enrolled in the series of studies at different points in time. The first 20 children and 
adolescents with HeFH who fulfilled the inclusion criteria (above) and volunteered for the 
study were included in the pharmacokinetic evaluation (Study I) with 10 mg pravastatin 
(Figures 6 and 7). The clinical characteristics of the patients are described in Table 5. Of 
these 20 patients, 10 tested positive for the FH-Helsinki LDL receptor mutation, 6 patients 
for the FH-North Karelia LDL receptor mutation, and 4 patients exhibited defective 
cholesterol intake in the lymphocyte test. 
 
Altogether 35 children and adolescents (including the 20 patients in Study I) with HeFH 
were recruited for the long-term safety and efficacy study (Study III). The final number of 






































Time of pravastatin initiation by individual HeFH participants 
 
Figure 7. The figure shows the patients with heterozygous familial hypercholesterolemia enrolled 
in the series of studies. The gray dots represent the 20 patients who participated in the 
pharmacokinetic study (Study I); the dots with a black center represent the 16 patients selected for 
the non-cholesterol sterol study (Study IV); all 30 patients participated in the safety and efficacy 




follow-up and were thus excluded: one patient discontinued after six months of therapy 
due to persistent abdominal pain (subsequently diagnosed as lactose intolerance), one 
patient discontinued at baseline due to lack of motivation, and three patients violated the 
study protocol. Aside from having HeFH, all our patients were healthy and, before the 
study, none was taking daily medication. Of the 30 patients, 16 tested positive for the FH-
Helsinki LDL receptor mutation, 6 patients for the FH-North Karelia LDL receptor mutation, 
2 patients for the FH-Turku LDL receptor mutation, and 6 patients exhibited defective 
cholesterol intake in the lymphocyte test. The characteristics of the patients appear in 
Table 5. Of note is that the patients were seldom over weight, as the mean W/H, which 
represents the ratio of weight for height (W/H) to the mean W/H in the normal population of 
the same age and gender, in girls was 2.3 ± 14.7%(-20 – 27%), and in boys, 13.3 ± 24.1% 
(-11-58.0%). One patient had been smoking 20 cigarettes/day for three years.  
 
Pravastatin was administered to the HeFH patients at 10 mg per day, with a dose 
escalation by 10 mg at 2, 4, 6, and 12 months of follow-up (maximum dose 50 mg), until 
cholesterol level reached the target (≤ 5mmol/L) (Figure 6). The maximum dose was 
increased to 60 mg in the patients with an exceptionally high total cholesterol level (> 7 
mmol/L) after 50 mg pravastatin.  
 
All HeFH patients were encouraged to use plant stanol or sterol ester products regularly 
with pravastatin. Of the 30 participants of Study III, a subgroup of 16 patients, who 
reported regular use of the non-absorbable stanol ester products throughout the study, 
were included in Study IV. Of these 16 participants, 7, who had reached the target total 
cholesterol level of 5 mmol/L with one year of pravastatin therapy, were characterized as 
Group A patients (patients with a sufficient response to pravastatin), and 9 patients, who 
had not, as Group B patients (patients with an insufficient resonse to pravastatin). The 
characteristics of the patients appear in Table 5. In Group B patients, the maximum dose 
of pravastatin at one year was 40 mg in all nine patients, and in Group A patients, 40 mg in 






4.2.  Cardiac transplant recipients and healthy pediatric controls 
 
The pharmacokinetic study (Study II) comprised 19 pediatric and adolescent cardiac 
recipients receiving triple immunosuppressive medication. The patient characteristics 
appear in Table 5. One patient was included in the pharmacokinetic study, but was 
excluded from the efficacy and safety studies because he was transferred from the 
children’s hospital to an adult unit; this patient was replaced by another cardiac transplant 
recipient in Study V (Table 5). Since August 2001, according to the general treatment 
protocol of the Hospital for Children and Adolescents, 10 mg of pravastatin per day has 
been administered to all cardiac transplant recipients during either their annual control 
visits (patients who had undergone cardiac transplantation before the initiation of the 
study) or four to six weeks after transplantation (patients who underwent cardiac 
transplantation after the study initiation). The dose of pravastatin was maintained at 10 
mg/day because of potential safety concerns (e.g. cyclosporine is known to increase the 
plasma concentrations of pravastatin in adults, and transplant recipients receive a variety 
of different drugs that can affect their renal or hepatic function). 
 
In Study V, the cardiac transplant recipients were divided into two groups based on the 
angiography findings before pravastatin: those who had coronary abnormalities were 
classified as patients with TxCAD, and those who had normal coronary arterieswere 
classified as patients without TxCAD. In the recipients who received their graft before the 
initiation of our study (September 2001), this division was based on earlier annual 
angiographies (up to 2001). In the new recipients who received their graft after the 
initiation of the study, the patients were grouped according to the findings of an 
angiography performed three months after transplantation. The condition of the coronary 
arteries was also documented in 2005, after approximately four years of pravastatin 
therapy. 
 
The same cardiologist, unaware of the patients’ clinical conditions, evaluated the coronary 
angiographies in the transplant recipients. The findings were graded according to 
International Society for Heart and Lung Transplantation Registry guidelines.270 
 
The patients with TxCAD did not differ from the patients without TxCAD by age (11.0 ± 5.4 
y vs. 12.1 ± 4.6 y, P = 0.630), time from transplantation to the initiation time of pravastatin 
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therapy (2.4 ± 3.0 y vs. 4.0 ± 3.3 y, P = 0.416), weight (39.3 ± 21.2 kg vs. 41.7 ± 22.4 kg, P 
= 0.823), height (135.6 ± 22.9 cm vs. 141.2 ± 24.0 cm, P = 0.634), or body mass index 
(BMI) (19.7 ±  4.9 kg/m2 vs. 19.3 ±  5.3 kg/m2, P = 0.896). 
 
In both studies, the immunosuppressive protocol included triple therapy with cyclosporine 
in microemulsion formulation (17 patients) or tacrolimus (2 patients), methylprednisolone 
(19 patients), and azathioprine (18 patients), or mycophenylate mofetil (1 patient). The 
target cyclosporine whole-blood trough level (measured by RIA method, Cyclo-Trac, 
Diasorin, Minnesota, USA) was 300-500 µg/l at 1-4 weeks, 200-400 µg/l at 1-3 months, 
150-300 µg/l at 3-6 months, 150-250 µg/l at 6-12 months, and 100-200 µl/L after the first 
year, respectively. The cyclosporine dose was adjusted individually, according to through 
levels, to maintain sufficient immunosuppression and to avoid toxic side-effects, such as 
nephrotoxicity. Cyclosporine was given in two or three daily doses. The target tacrolimus 
whole-blood trough level (measured by fluoroimmunoassay, IMX-system, Abbott 
Diagnostics, Abbott Park, Illinois, USA) was 8 – 12 µg/l at 0 – 12 months, and 5 – 7 µg/l 
after the first year. Recommendations for daily methylprednisone dosage were 0.30 
mg/kg/d for one to four weeks, 0.25 mg/kg/d for 1 to 6 months, and 0.37 mg/kg/d given on 
every other day thereafter. For practical reasons, the older recipients (time from 
transplantation > 6 months) in Study II were randomly divided into two groups: those who 
received methylprednisone on the pravastatin pharmacokinetic study day, and those who 
received methylprednisone on the previous day. Azathioprine was recommended at 1 
mg/kg/d during the first six months and 1.4 mg/kg/d months thereafter. 
 
Antihypertensive therapy was used if blood pressure was repeatedly higher than the age-
specific reference values. Additional medication on the day of the pravastatin 
pharmacokinetic study was as follows (the number in parenthesis refers to the number of 
patients receiving the drug):  diltiazem (3), felodipine (5), nifedipine (1), furosemide (5), 
propranolol (3), atenolol (1), bisoprolol (1), valganciclovir (2), aciclovir (1), pivmesillinam 
(1), cephalexin (1), oxycarbazepine (1), and omeprazole (1).  
 
Study V included 21 healthy pediatric controls (10 girls). The healthy controls were 7 to 18 
years of age, and participated only in the baseline (without pravastatin) lipid, lipoprotein, 






5.1.  Pharmacokinetics of pravastatin 
 
In the pharmacokinetic studies, the patients, who had not previously received pravastatin, 
ingested a 10 mg oral dose of pravastatin (a half of Pravachol 20 mg tablet, Bristol-Myers 
Squibb, Epernon, France) with 150 mL water after an overnight fast. The cardiac 
transplant recipients ingested their morning medication with pravastatin. The patients were 
not allowed to eat less than 1.5 hours after administration of pravastatin in order to prevent 
possible food-drug interactions.262 Timed blood samples (1 ml each) for the determination 
of plasma pravastatin concentration were drawn from a cannulated vein into chilled tubes 
containing EDTA. In the children with HeFH, the samples were drawn before pravastatin 
administration and 0.5, 1, 1.5, 2, 3, 4, 8, and 10 hours later, and in the cardiac transplant 
recipients, before pravastatin and 0.5, 1, 1.5, 2, 3, 4, 8, 12, and 24 hours later. Two 
children with HeFH were sampled only for four hours due to their young age (4.9 and 6.0 
years). Plasma was separated within 120 minutes and stored at –20 °C until analysis. The 
maximum storage time before analysis was 12 months. The concentrations of pravastatin 
in plasma were measured by liquid chromatography-ionspray tandem mass spectrometry 
with use of the PE SCIEX API 3000 LC/MS/MS system (Sciex Division of MDS Inc, 
Toronto, Canada).271 The ion transition monitored was m/z 442 to m/z 269, and the limit of 
quantification for pravastatin was 0.25 ng/mL. The day-to-day coefficient of variation was 
7.8% at 1 ng/mL (n = 6). The limit of quantification was 0.25 ng ml-1.  
 
The pharmacokinetics of pravastatin were characterized by peak concentration in plasma 
(Cmax), time to peak concentration (tmax), elimination half-life (t1/2), and area under the 
plasma concentration-time curve from 0 to 24 hours [AUC(0-24 h)] in cardiac transplant 
recipients, and from 0 to 10 hours [AUC (0-10)] in HeFH patients. The Cmax and tmax were 
determined visually and taken directly from the original data. The terminal log-linear phase 
of the plasma concentration-time curve was identified visually for each curve. The 
elimination rate constant (ke) was determined by log-linear regression analysis of the log-
linear phase of the plasma drug concentration curve. The criteria were the following: 
regression coefficient > 0.900, three to six time points at the log-linear phase, and the time 
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interval was visually chosen to represent the elimination phase, rather than the terminal 
elimination phase. The t1/2 was calculated by equation t1/2 = ln2/ke. The AUC values were 
calculated with the linear trapezoidal rule with extrapolation to infinity, when appropriate, 
by division of the last measured concentration by ke. In order to compare the groups, AUC 
(0-10) values of the cardiac transplant recipients were calculated by estimating the 
concentrations at ten hours with the help of the elimination curve. The two FH-patients 
who were sampled for only four hours owing to young age, and one FH-patient whose 
terminal log-linear phase of the plasma drug concentration curve had only two time points, 
were excluded from the t1/2 and AUC analyses.  
 
5.2.  Efficacy of pravastatin 
5.2.1.  Lipid and lipoprotein determinations in HeFH patients  
 
The fasting (at least 10 hours) concentrations of serum total, LDL, and HDL cholesterol 
and of serum triglycerides were determined before and at 1, 2, 4, 6, 12, and 24 months of 
pravastatin treatment (Study III). The concentrations of serum total and HDL cholesterol 
and of serum triglycerides were analyzed enzymatically by use of HITACHI 917 or 
MODULATOR automatic analyzers with reagents and calibrators as recommended by the 
manufacturer (Roche Diagnostics, Basel, Switzerland). The inter-assay coefficients of 
variation for low and high serum cholesterol concentrations (3.3 mmol/L and 7.1 mmol/L), 
HDL cholesterol concentrations (0.9 mmol/L and 1.6 mmol/L), and triglyceride 
concentrations (1.0 mmol/L and 2.0 mmol/L) were 2.1% and 1.8%, 2.2% and 2.7%, and 
3.0% and 2.3%, respectively. The LDL-cholesterol concentration was calculated from the 
formula of Friedewald et al.272 In the 30 HeFH patients, the highest fasting concentrations, 
prior to dietary or drug interventions, of serum total, LDL, and HDL cholesterol and of 
serum triglycerides were recorded from the patient chart. The response to dietary therapy 




5.2.2.  Noncholesterol sterols in HeFH patients 
 
In Study IV, the 16 participants were grouped as Group A patients (those who reached the 
target total cholesterol 5 mmol/L after one year of pravastatin) and Group B patients (those 
who did not reach the target total cholesterol 5 mmol/L after one year of pravastatin) 
according to the total cholesterol concentrations obtained in Study III. The serum total 
cholesterol and non-cholesterol sterols in Study IV were measured by gas-liquid 
chromatography (GLC) on a 50-m-long capillary column (Ultra 2, 5890, Hewlett Packard, 
Littlefalls (Wilmington), Delaware, USA) from frozen (-20°C) serum samples drawn at 
baseline and at 2, 6, and 12 months of pravastatin treatment. Because serum non-
cholesterol sterols are transported mainly in cholesterol-containing particles, the absolute 
concentrations were adjusted for serum cholesterol analyzed by the same GLC run, and 
are expressed as ratios (102 x mmol/mol cholesterol). The ratios of cholestanol, 
campesterol, and sitosterol are referred to as absorption markers of cholesterol, and those 
of desmosterol and lathosterol, as cholesterol synthesis markers.  
 
5.2.3. Lipid, lipoprotein and apolipoprotein determinations in cardiac 
transplant recipients and in healthy pediatric controls 
 
In Study V, venous blood samples for the lipoprotein analysis were collected in the 
morning after a fasting period of at least eight hours in the pediatric cardiac transplant 
recipients before and after one year of pravastatin, and in the healthy controls without 
pravastatin at baseline. Serum was separated by low-speed centrifugation (2000 rpm/10 
minutes at + 5 ˚C), divided into aliquots, and stored at -70˚ C until lipid and lipoprotein 
analysis. Parts of the aliquots without freezing were immediately used for lipoprotein 
separation and some were frozen at -20 ˚C for a maximum of 12 weeks until lipoprotein 
separation. 
 
Serum lipoproteins were separated by sequential ultracentrifugation using Optima TL 
Ultracentrifuge and Tl 100.3 rotor (Beckman Instruments, Palo Alto, CA, U.S.A.) at the 
densities adjusted with KBr: VLDL (< 1.006 g/ml, 100000 rpm/  h), IDL (1.006 - 1.019 g/ml, 
100000 rpm/2 h), LDL (1.019  - 1.063 g/ ml,100000 rpm/2 h), HDL2 (1.063 – 1.125 
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g/ml,100000 rpm/3 h). A bottom fraction of d >1.125 g/ml represented HDL3 fraction. 
Isolated lipoprotein subfractions were frozen at -20 ˚ C (2-12 weeks) until the completion of 
lipid and total protein determinations.  
 
Serum and lipoprotein subfractions were analyzed for total cholesterol and triglycerides 
with an automated Optima analyzer (Thermo Electron Corporation, Vantaa, Finland) by 
fully enzymatic methods (Thermo Electron Corporation kits 981812 and 981301). Serum 
HDL cholesterol was quantified with a homogenous enzymatic test with polyethylene 
glycol (PEG) modified enzymes (Thermo Electron Corporation kit 981655). Serum LDL 
cholesterol was calculated with the formula of Friedewald et al.272 
 
Serum concentrations of apoA-I, apoA-II, and apoB-100 were measured by 
immunoturbidometric methods using an Optima analyzer (for apoA-I and apoB-100, 
Thermo Electron Corporation kits 981662 and 981663; for apoA-II, Thermo Electron 
Corporation and polyclonal antibodies produced in rabbits against apoA-II). Phospholipids 
in lipoprotein fractions were measured using a colorimetric enzyme method273 (Wako 
Chemicals GmbH, Germany kit 990-54009). 
 
It is important to note that in the transplant recipients, the serum lipoproteins were thus 
analyzed by two separate methods: i) In order to determine and calculate the specific 
mass composition of the major lipoproteins, the lipoprotein fraction was separated from the 
others by ultracentrifugation, and its content of triglycerides, cholesterol, phospholipids, 
and proteins was determined. ii) In order to determine the serum levels of lipids or 
lipoproteins, serum samples were analyzed by the same enzymatic lipid assay methods in 
order to derive serum total amounts of triglycerides, cholesterol, and HDL cholesterol. LDL 
cholesterol was then calculated by using the Friedewald equation.272 These results differ 





5.3.1. Adverse events 
 
 The potential side-effects of pravastatin were monitored using a systematic questionnaire 
that the patients or the parents or both (depending on the age of the patient) completed at 
home before each control visit: in children with HeFH at 2, 4, 6, 12, and 24 months of 
pravastatin administration, and in the cardiac transplant recipients, at 2 months. The 
presence of similar symptoms prior to statin therapy was also recorded. 
 
5.3.2. Biochemical safety 
 
Clinical examinations and biochemical measurements of safety, including serum alanine 
aminotransferase (ALT), creatine kinase (CK), and creatinine concentrations were 
performed in the children with HeFH before treatment and at 2, 4, 6, 12, and 24 months, 
and in the cardiac transplant recipients (participants of Study IV), before treatment and at 
12 months. In the HeFH patients, vitamins A, D, and E were determined before treatment 
and at 6, 12, and 24 months. The vitamins A and E were analyzed by high-performance 
liquid chromatography (Hewlett Packard Waldbronn, Germany), 1.25-hydroxyvitamin D by 
radioimmunoassay (Wallac, Turku, Finland), and 25-hydroxyvitamin D by 
radioimmunoassay (DiaSorin, Stillwater, USA) or by the HPLC-method.274 In the cardiac 
transplant recipients, the glomerular filtration rate was determined by 51Cr EDTA clearance 
before and at one year of pravastatin: a 51Cr EDTA injection (2 uCi/kg, maximum 100 uCi) 
was given, after which blood samples were collected at 90, 150, 210 and 270 min. The 
urinary clearance of 51Cr EDTA was calculated from the rate of 51Cr EDTA disappearance 
from serum. The clearances obtained were corrected for a standard body surface area of 
1.73 m2.  The results were considered reliable if the distribution volume of the injection 






5.3.3. Growth in HeFH patients 
 
 The height and weight of the 30 patients with HeFH in Study III were measured with a 
wall-mounted stadiometer and an electric scale during each visit. The hSDS was 
calculated according to the following equation: hSDS = (observed height – mean height for 
age)/SD, where SD represents the standard deviation for the normal population of the 
same chronologic age (CA) and gender.275 The weight for height index (W/H), expressed 
as a percentage, was determined from the ratio of weight (kg) for height (cm) to the mean 
W/H in the normal population of the same CA and gender. Bone age (BA) was determined 
at each visit according to the Greulich-Pyle method276 by the same pediatric 
endocrinologist. Height for bone age (hBA) was also calculated and expressed as a 
standard deviation score.275 The growth, in relation to gender and pubertal stage, of each 
patient was individually evaluated by a pediatric endocrinologist using growth charts, 
clinical data (e.g. changes in ΔhSDS and W/H, pubertal development, time of menarche), 
hormonal results (estradiol, testosterone), and bone age measurements. 
 
5.3.4. Development in HeFH patients  
 
The pubertal maturation of the 30 patients with HeFH was evaluated clinically by using 
Tanner’s pubertal staging, by the same pediatrician during each visit.277-280 Early 
maturation was defined as the development of sexual characteristics before the age of 
eight years in girls and nine years in boys. Delayed puberty was defined as exhibiting no 
signs of puberty at the age of 13 years in girls and at 14 years in boys (2 SD above the 
mean of chronological age for the onset of puberty in Caucasians).277, 278, 281-283 The 
menstrual history in girls was recorded. Gonadal maturation in girls was assessed with 
ultrasonography by a pediatric gynecologist at baseline (in 13 girls), at 12 months (in nine 
girls), and at 24 months (in two girls). The ultrasonography was performed 
transabdominally through a distended bladder with an Aloka SSD-1100 ultrasound 
scanner equipped with a 13 MHz probe. The length of the uterus was recorded. The 
ovarian structure was evaluated, and the ovarian volume was calculated by: thickness x 
length x width x 0.52. Testis volume in boys was assessed by high-resolution B-mode 
ultrasonography (using an ATL HD 5000 ultrasound scanner equipped with a linear 5-12 
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MHz transducer) before treatment and at 12 and 24 months. The testis volume was 
calculated by: thickness x length x width x 0.52.284 
 
Baseline and stimulated hormonal status was recorded at 0, 12, and 24 months, 
comprising baseline adrenocorticotropic hormone (ACTH), testosterone, and estradiol 
levels and ACTH stimulated cortisol secretion, gonadotropin releasing hormone (GnRH) 
stimulated follicle-stimulating hormone (FSH) and luteinizing hormone (LH) secretion. In 
the GnRH stimulation test, the patient received a dose of 3.5 µg/kg of GnRH (maximum 
dose 100 µg), and blood samples for LH and FSH measurements were collected at 0, 20, 
30, and 60 minutes, and at 0, 30, 60, and 90 minutes, respectively.285 In the ACTH 
stimulation test, the patient received a dose of 0.25 mg/1.73 m2 of ACTH (maximum dose 
0.25 mg), and blood samples for cortisol measurements were collected at 0, 60, and 120 
minutes. All laboratory measurements were carried out according to the standards of the 
Helsinki University Central Hospital. Serum FSH and LH were quantitated with time-
resolved ultrasensitive immunofluorometric assays (AutoDELFIA™, Wallac, Turku, 
Finland). Serum estradiol, testosterone, and ACTH were measured by radioimmunoassay 
(Wallac, Turku, Finland). Serum cortisol was quantitated with an enzyme immunoassay 
and with reagents on the immunoanalyzer Immunol® (Bayer, Tarrytown, USA). 
 
The boys and girls were divided into subgroups (I A, prepubertal at baseline and at follow-
up; I B, prepubertal at baseline and pubertal at follow-up; II, pubertal at baseline; III, 
postpubertal at baseline) according to the results of the GnRH stimulation test and clinical 
examination: prepubertal was defined in clinical examination as Tanner stage 1, and peak 
FSH dominant over peak LH in the GnRH stimulation test; pubertal was defined as peak 
LH dominant over FSH, and peak LH concentration > 6 IU/L in the GnRH stimulation test; 
and postpubertal was defined in clinical examination as Tanner stage 5, and in girls, 
menarche before the onset of this study. The GnRH stimulation test was used because of 
its sensitivity in detecting central puberty before clinical signs. The development, relative to 
age and gender, of each patient was individually evaluated by the use of clinical data (e.g. 
progression in puberty, time of menarche), hormonal results (GnRH stimulation test, 




5.4. Statistical analysis 
 
Data are mean ± SD in text and tables (except from triglycerides, median and range). The 
normality of the distribution was tested with the Shapiro-Wilk W test. Repeated measures 
analysis of variance (ANOVA) was used to assess changes in the concentrations at 
different time points. Friedman’s non-parametric test was used to analyze differences 
between time points when the assumptions of the repeated measures analysis of variance 
were not met. In HeFH patients, all 30 patients participated to the 0 to 12 months follow-
up, whereas 14 patients (out of 30) were followed for 24 months. Therefore, both analyzes 
from 0 to 12 months (in 30 patients) and from 0 to 24 months (14 patients) was performed. 
When only 2 measurement points were available, statistical comparison of the normally 
distributed variables between the pretreatment and treatment phases was carried out with 
the paired t test. If the distribution was skewed, the Wilcoxon signed rank test was used. 
Statistical comparison of the normally distributed variables between different groups was 
carried out with the student t-test for unpaired values, and with the Mann-Whitney test if 
the distribution was skewed. Pearson´s correlation coefficients were calculated to evaluate 
degrees of linear association between normally distributed variables and Spearman´s rank 
correlation coefficients for nonparametric variables. The statistics software used was from 
StatsDirect Ltd, Cheshire, UK. P values below 0.05 were considered statistically 
significant. 
 
5.5.  Ethical considerations 
 
The study protocol was approved by the Ethics Committee of the Helsinki University 
Hospital for Children and Adolescents and by the National Agency for Medicines in 
Finland. Each patient participated on a voluntary basis. Written informed consent was 





6.1. Pharmacokinetics of pravastatin in children with HeFH and in cardiac 
transplant recipients 
The mean pravastatin plasma concentration curves in the children with HeFH and in the 
cardiac transplant recipients appear in Figure 8, and the pharmacokinetic parameters, in 





















Figure 8. Mean plasma pravastatin concentrations (± SD) after a single oral dose of 10 mg pravastatin in 19 
pediatric cardiac transplant recipients on triple immunosuppression (black squares), and in 20 children with 




























Compared to the children with HeFH, the pediatric cardiac transplant recipients exhibited a 
nearly ten-fold higher mean Cmax and AUC (0-10) of pravastatin. In both groups, the inter-
individual variability in the Cmax and AUC(0-10) values was considerable. A significant 
inverse correlation in the HeFH patients emerged between the Cmax and age (r = -0.52; P = 
0.020), weight (r = -0.50; P = 0.026), and body surface area (r = -0.51; P = 0.022). Similar 




Table 6. Pharmacokinetic parameters with 10 mg pravastatin in 19 pediatric cardiac transplant recipients on 
triple immunosuppression and in 20 children with heterozygous familial hypercholesterolemia. 
  Cmax Tmax AUC(0-10) t½ 
      





15.7 ± 14.4 
1.6 – 55.0 
1.25 
0.5 – 4 
27.8 ± 16.7 
6.5 – 58.9 
1.7 ± 0.7 





mean ± SD 
range 
122.2 ± 88.2 
11.4 - 305.0 
1 
0.5 – 2 
264.1 ± 192.4 
30.8 – 701.6 
1.2 ± 0.3 
0.9 – 2.2 
P-value  < 0.0001 0.065 < 0.0001 0.001 





6.2.1. Efficacy of dietary and pravastatin interventions in HeFH children 
The highest total and LDL cholesterol concentrations prior to dietary or drug interventions 
in the children with HeFH were 9.1 ± 1.4 mmol/L and 7.2 ± 1.4 mmol/L, respectively. The 
dietary intervention (consisting of a low-fat, reduced-saturated-fat, and low-cholesterol diet 
with supplementation of plant stanol or sterol esters) lowered the total and LDL cholesterol 
concentration significantly (-10.7%, P <0.0001 and -12.6% P =0.0001, respectively). The 
HDL cholesterol concentrations and triglycerides prior to dietary or drug interventions were 
1.4 ± 0.3 mmol/L and 1.0 ± 0.5 mmol/L , respectively; an insignificant increase during 
dietary intervention occurred in the serum triglyceride levels (19.2%, P =0.728), whereas 
the HDL cholesterol concentrations remained unaffected (0.4%, P =0.841).  
 
Figure 9 shows the serum total, LDL and HDL cholesterol concentrations, and triglycerides 
in the 30 children and adolescents with HeFH before pravastatin (during diet) and at 2, 4, 
6, and 12 months of pravastatin. When compared to the pre-treatment values, at 2, 4, 6, 
12, and 24 months of treatment, the total cholesterol levels had decreased by 19%, 20%, 
23%, 27%, and 26%, and the LDL cholesterol levels by 25%, 27%, 29%, 33%, and 32%. 
The respective decreases in the triglyceride concentrations were 5%, 3%, 3%, 11%, and 
34%, and the increases in HDL cholesterol concentrations 5%, 8%, 2%, 4%, and 11%. 
The reductions in total and LDL cholesterol concentrations and triglyceride levels (both in 
the whole patient group from 0 to 12 months and in the subgroup of 14 patients from 0 to 
24 months) were statistically significant (P-values not shown). The increase in HDL 
cholesterol concentration from 0 to 12 months was also significant. Approximately 70 to 
80% of the maximum total and LDL cholesterol-lowering efficacy was achieved with 10 to 
20 mg pravastatin. The mean maximum reduction in total cholesterol was 32.4 ± 7.9%, but 
the cholesterol-lowering efficacy did vary considerably: e.g. in one girl, 10 mg pravastatin 
reduced the total cholesterol concentration by 46.3%, whereas in another patient, 40 mg 
pravastatin yielded only a 7.0% reduction in cholesterol. The total cholesterol 
concentrations reached the target level (≤ 5 mmol/L) in nine of the 30 patients after one 




6.2.2. Noncholesterol sterols in patients with HeFH 
To determine whether differences in cholesterol absorption and synthesis could explain 
the considerable differences in the responsiveness to pravastatin observed in Study III, 
we divided the participants of Study IV into those with sufficient response to pravastatin 
(Group A: patients who reached the target total cholesterol of 5 mmol/L by one year of 
pravastatin) and those with insufficient response to pravastatin (Group B; patients who 
failed to reach the target). Besides pravastatin, the patients in both groups used similar 
amounts of plant stanol ester products (2 g daily). The Group B patients with an insufficient 
response to pravastatin had higher study baseline (on plant stanol esters) serum 
cholesterol concentrations (7.7 ± 1.0 vs. 6.5 ± 0.9 mmol/L, P < 0.001) and higher 
respective ratios of campesterol (371 ± 99 vs. 277 ± 67 102 x mmol/mol of cholesterol, P = 
0.049) and sitosterol (176 ± 37 vs. 126 ± 24 102 x mmol/mol of cholesterol, P = 0.008) than 
did Group B patients (Figure 10). In general, the higher the ratio of cholestanol to 
cholesterol at study baseline, the smaller the one-year reduction in cholesterol (Figure 11). 
Overall, pravastatin decreased the serum levels of cholesterol, and cholesterol synthesis 
markers, and increased the ratios of cholesterol absorption markers. These effects were 






Figure 9. Total, LDL, and HDL cholesterol concentrations and triglycerides in children with HeFH before and 
during pravastatin treatment with increasing doses (maximum dose 10 to 60 mg). The mean concentrations 
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Figure 10. Mean ratios of serum cholestanol, campesterol and sitosterol (absorption markers), and 
desmosterol and lathosterol (synthesis markers) to cholesterol in 7 Group A patients (those with a sufficient 
response to pravastatin after one year) and in 9 Group B patients (those patients with an insufficient 
response to pravastatin after one year) during pravastatin therapy in increasing doses. † Indicates statistical 
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Figure 11. The correlation between the baseline ratio of cholestanol to cholesterol and the one-year 
reduction (%) in cholesterol in 7 Group A patients (those with a sufficient response to pravastatin after one 
year; solid circles) and 9 Group B patients (those with an insufficient response to pravastatin after one year ; 
open circles). 
 
6.2.3.  Lipids, lipoproteins, and apolipoproteins in cardiac transplant 
recipients 
Figure 12 shows the serum total, LDL, and HDL cholesterol concentrations and triglyceride 
levels of the cardiac transplant recipients before pravastatin and at one year, and of 
healthy pediatric controls without pravastatin at baseline. Of note is that, compared to the 
healthy controls, the serum total and LDL concentrations of the transplant recipients were 
not elevated. However, both before pravastatin and at one-year, the serum HDL 
cholesterol concentrations of the recipients were significantly lower (P = 0.003 and P = 
0.009, respectively), and the serum triglyceride levels were significantly higher (P = 0.0004 
and P = 0.0002, respectively). A negative correlation between serum triglycerides and 

























r = 0.556 
P = 0.025 
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HDL cholesterol levels emerged in cardiac transplant recipients prior to pravastatin therapy 
(r = -0.523, P = 0.022), and a similar tendency was also observed after one year of 
pravastatin (r = -0.439, P = 0.060).  
 
Table 7 demonstrates the mean concentrations of cholesterol and triglycerides in 
lipoproteins in transplant recipients (at baseline and at one year) and in controls (at 
baseline). The quantity of triglycerides in LDL, VLDL and IDL particles was persistently 
high in the transplant recipients than in the controls (Table 7). Furthermore, the baseline 
apoB-100/apo-A1 ratios in the recipients were higher, and the HDL2 cholesterol 
concentration, lower (Table 7).  
 
After one year of treatment, pravastatin (10 mg per day) had statistically significantly 
lowered the serum total cholesterol by 10.0 ± 14.6% (P = 0.006) and serum LDL 
cholesterol by 19.1 ± 24.2% (P = 0.002). HDL cholesterol increased by 5.7 ± 26.4% (P = 
0.542). Of note, serum triglycerides slightly, yet non-significantly (10.2 ± 48.7%; P = 0.836) 
increased, rather than decreased, during pravastatin intervention. Furthermore, the 
reductions in apo-B level (0.8 ± 0.2 to 0.7 ± 0.2; P = 0.005) and apo-B/apo-A1 ratio (0.6 ± 
0.2 to 0.5 ± 0.1; P = 0.004) were also statistically significant. 
 
6.2.4. Lipids, lipoproteins and apolipoproteins in association to TxCAD 
The patients with TxCAD had significantly lower serum HDL cholesterol concentrations at 
baseline (1.0 ± 0.3 mmol/L vs. 1.4 ± 0.3 mmol/L, P = 0.031) and at one year of pravastatin 
(1.0 ± 0.3 mmol/L vs. 1.4 ± 0.3 mmol/L, P = 0.013), and a significantly higher percentage 
of triglycerides in the LDL particles at baseline (12.4 ± 2.6% vs. 8.2 ± 1.7%) than did the 
patients without accelerated coronary artery disease (TxCAD). Furthermore, the patients 
with TxCAD also exhibited a significantly lower concentration of cholesterol in the HDL2 
particle at one year, and a significantly higher ratio of apoB/apoA1 at baseline and at one 





   
Figure 12. Lipid and lipoprotein levels of 19 pediatric and adolescent cardiac transplant recipients before and 
at one year of pravastatin treatment (10 mg/day), and of 21 healthy pediatric controls at baseline (without 
pravastatin). Open circles represent the cardiac transplant recipients without TxCAD. Closed black circles 
represent the transplant recipients with TxCAD. Vertical lines mark the mean concentrations (except for 
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Table 7. Concentrations of cholesterol and triglycerides in lipoproteins in cardiac transplant recipients at baseline and at one year of 
pravastatin, and in healthy pediatric controls at baseline. 
 

















At baseline without pravastatin 
       
LDL  C (mmol/L) 2.26 ± 0.86 2.29 ± 0.53 0.938 2.28 ± 0.63 1.84 ± 0.44 0.014 
 TG (mmol/L) 0.30 (0.13-0.51) 0.22 (0.14-0.30) 0.204 0.22 (0.13-0.51) 0.13 (0.09-0.22) < 0.0001 
VLDL C (mmol/L) 0.45 ± 0.28 0.29 ± 0.19 0.166 0.34 ± 0.23 0.21 ± 0.14 0.038 
 TG (mmol/L) 0.66 (0.46-1.99) 0.51 (0.17-1.28) 0.312 0.53 (0.17-1.99) 0.28 (0.07-1.14) 0.007 
IDL C (mmol/L) 0.32 ± 0.17 0.22 ± 0.12 0.176 0.26 ± 0.14 0.31 ± 0.12 0.162 
 TG (mmol/L) 0.22 (0.17-0.48) 0.17 (0.08-0.36) 0.067 0.19 (0.08-0.48) 0.15 (0.03-0.26) 0.014 
HDL2 C (mmol/L) 0.56 ± 0.16 0.70 ± 0.35 0.351 0.66 ± 0.30 0.86 ± 0.24 0.021 
 TG (mmol/L) 0.09 (0.04-0.12) 0.07 (0.02-0.21) 0.743 0.08 (0.02-0.21) 0.07 (0.04-0.17) 0.453 
ApoA-I ‡ (g/L) 1.2 ± 0.3 1.4 ± 0.2 0.072 1.3 ± 0.3 1.5 ± 0.2 0.059 
ApoB-100‡ (g/L) 0.9 ± 0.3 0.7 ± 0.2 0.220 0.8 ± 0.2 0.6 ± 0.1 0.032 
ApoB-100‡ 
ApoA1 
─ 0.7 ± 0.2 0.5 ± 0.1 0.034 0.6 ± 0.2 0.4 ± 0.1 0.005 
 
At one year of pravastatin 
       
LDL C (mmol/L) 1.82 ± 0.64 1.55 ± 0.46 0.309 1.64 ± 0.52 ─ 0.184 
 TG (mmol/L) 0.16 (0.13-0.27) 0.18 (0.13-0.28) 0.747 0.17 (0.13-0.28) ─ 0.002 
VLDL C (mmol/L) 0.44 ± 0.16 0.30 ± 0.18 0.113 0.34 ± 0.18 ─ 0.014 
 TG (mmol/L) 0.91 (0.31-1.20) 0.58 (0.20-2.0) 0.101 0.64 (0.20-2.0) ─ 0.0004 
IDL C (mmol/L) 0.38 ± 0.17 0.40 ± 0.24 0.885 0.39 ± 0.22 ─ 0.394 
 TG (mmol/L) 0.21 (0.15-0.27) 0.22 (0.11-0.43) 0.684 0.22 (0.11-0.43) ─ 0.0001 
HDL2 C (mmol/L) 0.60 ± 0.12 0.93 ± 0.24 0.006 0.83 ± 0.26 ─ 0.660 
 TG (mmol/L) 0.08 (0.06-0.10) 0.13 (0.06-0.16) 0.107 0.08 (0.06-0.16) ─ 0.011 
ApoA-I ‡ (g/L) 1.2 ± 0.2 1.4 ± 0.2 0.085 1.3 ± 0.2 ─ 0.045 
ApoB-100‡ (g/L) 0.7 ± 0.2 0.6 ± 0.1 0.156 0.7 ± 0.2 ─ 0.826 
ApoB-100‡ 
ApoA1 
─ 0.6 ± 0.2 0.4 ± 0.1 0.005 0.5 ± 0.1 ─ 0.143 
Data are mean ± SD, except for triglycerides median (range). TxCAD, transplant coronary artery disease; C, cholesterol; TG, 
triclycerides. 
* Patients with TxCAD are compared to patients without TxCAD. 
† All cardiac transplant recipients before or at one year of pravastatin are compared to the healthy controls at baseline.   




Table 8. The coronary changes detected by angiography in 19 pediatric cardiac transplant recipients before and 
after four years of pravastatin intervention (10 mg/day). 
Patients Coronary status 
prior to pravastatin 
Coronary status 
after four years of pravastatin 
Clinical observations 
during 4 years of pravastatin 
    
1 15% stenosis in RCA 30% stenosis in RCA grade I rejection 
 
 
2 20% stenosis in RCA 20%stenosis in LAD 
35% stenosis in RCA 
 
─ 
3 50% stenosis in LCX progressed up to 95% stenosis 
in LCX 
 
underwent a stent operation 





5 15% stenosis in LAD 
15% stenosis in RCA 
25% stenosis in LAD 
20% stenosis in RCA 
 two grade I rejections 
nonadherence to therapy 
 
6 severe vasculopathy severe vasculopathy 
 
 
died of TxCAD 
 
7 normal 30% stenosis in LAD 
 
 
two grade I rejections 
 
8 normal 30% stenosis in LCX 
 
grade I rejection 
metabolic syndrome* 
 




10 normal normal 
 
grade II rejection 
 




12 normal normal 
 
─ 
13 normal normal 
 
─ 
14 normal normal 
 
─ 
15 normal normal 
 
─ 
16 normal normal 
 
─ 
17 normal normal 
 
─ 




19 normal normal 
 
─ 
TxCAD, transplant vasculopathy; RCA, right coronary artery; LAD, left anterior descending coronary artery;     
LCX, left circumflex artery.                                    




6.2.5.  Changes in coronary status during pravastatin intervention 
Table 8 represents the coronary changes detected by angiography in cardiac transplant 
recipients before and after approximately four years of pravastatin therapy, and the 
observed rejections after the initiation of pravastatin. Of the six patients with TxCAD at 
baseline (prior to pravastatin), one had died of severe coronary vasculopathy, and one had 
undergone stent operation. In the remaining four patients, the coronary changes remained 
unchanged or only minor progression occurred. Of the 13 patients with healthy coronaries 
at baseline (patients without TxCAD), 2 had developed 30% stenotic coronary changes 
during pravastatin intervention. A preceding grade I rejection occurred in both patients. 
Coronary angiographies of 11 patients without TxCAD remained normal during the four- 
year pravastatin intervention.  
 
6.3. Safety 
6.3.1. Adverse events in HeFH patients  
The adverse events reported by the 30 children with HeFH with one to two years of 
pravastatin therapy appear in Table 9. The most common adverse experiences were 
headache and gastrointestinal symptoms, affecting at two months 13% and 37% of the 
patients, respectively. These were, however, common complaints before treatment as well, 
affecting 10% and 17% of the patients. Most symptoms were mild and disappeared during 
the first months of therapy. During the up to two year follow-up of the FH-patients in Study 






6.3.2. Adverse events in cardiac transplant recipients 
During the two-month follow-up, 11% of the cardiac transplant recipients reported muscle 
tenderness or pain associated with physical training, while no abdominal pain, loose 
stools, or sleeping disturbances took place. Headaches occurred in 42% of the cardiac 
transplant recipients, but its frequency remained unchanged, since eight patients reported 
headache before and eight patients did so during pravastatin therapy.  During the four-
year follow-up of the cardiac transplant recipients in Study V, no serious side-effects 
occurred that would have required discontinuation of pravastatin therapy. 
 
6.3.3. Biochemical safety in HeFH children 
The ALT, CK and creatinine values of the children with HeFH before pravastatin and at 2, 
4, 6, 12 and 24 months appear in Figure 13A. Although some elevations in these 
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concentrations were statistically significant, they were clinically insignificant. The vitamin 
levels of the 30 children with HeFH that were followed for one to two years of pravastatin 
therapy appear in Figure 13B: although the changes in vitamin E concentrations were 
statistically significant, all concentrations remained within the reference (12 – 40 umol/L). 
During follow-up, no statistically significant changes in the vitamin A concentrations took 
place; however two individual patients exhibited vitamin A concentrations (0.8 -0.9 umol/L) 
slightly lower than the reference (1 – 3 umol/L). A statistically significant increase in the 
1.25-hydroxyvitamin D levels also occurred. 
 
6.3.4. Biochemical safety in cardiac transplant recipients 
 
The CK, creatinine and ALT values in the 19 pediatric cardiac transplant recipients before 
pravastatin and at 2, 4, 6, and 12 months appear in Figure 14 (unpublished data).  No 
clinically or statistically significant elevations in these parameters occurred during 
pravastatin. The mean GFR before pravastatin was 78.8 ± 25.4, and at one year, was 75.5 
± 28.2 (P = 0.579). 
 
6.3.5. Growth in HeFH children 
The parameters regarding growth and development appear in Table 10. The boys and girls 
were divided into subgroups (I A, prepubertal at baseline and at follow-up; I B, prepubertal 
at baseline and pubertal at follow-up; II, pubertal at baseline; III, postpubertal at baseline) 
according to results from the GnRH stimulation test and clinical examination (please see 
Methods).  Growth, as individually evaluated, and related to age, gender, and pubertal 
stage, was normal in all patients.  At baseline, the two boys (9.8 and 10.7 years of age) 
with HeFH in Group II were pubertal according to the GnRH stimulation test (LH dominant 
over FSH, peak LH 6.7 IU/L in both), but had prepubertal testicular volumes (< 4 ml). Their 
mean height velocity at one year was at > 97th percentile. However, at two years, the 
height velocity of one of the boys had normalized to ~ 97th percentile. The growth of these 
two boys, as individually analyzed by using growth charts, was normal, and no accelerated 

























Figure 13. Serum alanine aminotransferase, creatinine and creatine kinase concentrations (mean and SD) 
before pravastatin treatment and at 2, 4, 6, 12, and 24 months (Figure A), and serum fat-soluble vitamin 
concentrations (mean and SD) before treatment and at 6, 12, and 24 months (Figure B) in children and 
adolescents with familial hypercholesterolemia. † Indicates that the changes in both the concentrations 0 to 
12 months (30 patients) and 0 to 24 months (14 patients) are statistically significant (P ≤ 0.05) in ANOVA. ‡ 
Indicates that the changes 0 to 24 months (14 patients) are statistically significant (P ≤ 0.05) in ANOVA . 
Vitamin E †    25-Hydroxy-     1.25-Hydroxy-     Vitamin A 
           vitamin D ‡       vitamin D † 
(scale on left)   (scale on left)       (scale on left)   (scale on right) 
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Figure 14. Serum creatine kinase (CK), creatinine, and alanine aminotransferase (ALT) concentrations 
(mean and SD) before and at 2, 4, 6, and 12 months of pravastatin (10 mg/d) in 19 pediatric cardiac 
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6.3.6. Development in HeFH children 
 The estradiol and testosterone concentrations appear in Table 11; we observed no 
abnormal changes, and at baseline, no signs of early maturation or delayed puberty. 
Pubertal development, as individually evaluated and related to age and gender, was 
normal in all patients. The measurements of uterus and ovaries or testicles, with reference 
values, appear in Table 11. The ovarian structure, related to age, was normal in all the 
patients examined. The testis volumes of pubertal boys (Group IB and II) were lower than 
the reference. This might partly be due to a difference in definition, as the GnRH 
stimulation test can detect central puberty before clinical signs. 
 
      15.6 ± 1.7 
      24.6 ± 4.0 
    168.3 ± 4.7 
        0.7 ± 0.7 
Boys 
                        At baseline 
kg/m2 
Table 10. Growth in girls and boys with heterozygous familial hypercholesterolemia in up to 2 years of pravastatin treatment.
Group    ∆ 0 to 1 y 
Chronological age years I A        7.1 ± 2.3     
I B 9.7; 9.8 
II      12.2 ± 0.7 
IIi     15.9 ± 1.9 
Height (hSDS) SD I A       0.1 ± 0.5 
I B 0.5; 0.6  
II  
III        0.8 ± 0.5 
Height * cm I A   122.2 ± 14.8 
I B 139.7; 141.0 
II    156.7 ± 3.7 
III
Weight for height index % I A      2.33 ± 15.7 
I B -12.0; -1.0 
II       -2.7 ± 11.9 
III      19.7 ± 11.8† 
Body mass index I A     16.3 ± 2.5 
I B 14.6; 16.6 
II      18.0 ± 2.0 
III
Bone age years I A        6.6 ± 2.2 
I B 8.0; 8.8 
II      12.8 ± 0.8 
III
Height for bone age  SD I A         0.5 ± 0.4 
I B 1.3; 2.4 
II        0.2 ± 0.9 





       0.2 ± 0.2
      -0.2 ± 0.2 
      -0.1 ± 0.1 
       7.0 ± 1.0
4.1 ± 1.8
0.5 ± 0.6 
0.5 ± 3.1 
2.7 ± 4.0
4.3 ± 3.9
0.4 ± 0.6 
0.8 ± 0.7 
0.4 ± 1.3 
1.3 ± 0.3
1.4 ± 0.4 
1.0 ± 0.7 
      0.03 ± 0.5 
      -0.2 ± 0.2
      -0.2 ± 0.2
∆ 1 to 2 y 
         0.0; 0.3 
       -0.5 ± 0.3 
         6.2; 8.3
        -1.0; 9.0 
         0.4; 2.5 
         1.2; 1.5





       -0.1; 0.0
         0.2; 0.3 
           -0.1 
5.4 ± 0.1
        7.6; 8.4
1.5 ± 1.2 
            0.2 
         1.0; 5.0 
        -5.0; 1.0
2.5 ± 3.3 
         13.0
        0.6; 1.0
—
0.6 ± 0.6 
            2.4 
        1.0; 1.2
         1.0; 1.5 
0.7 ± 0.3
            1.0 
       -0.1; -0.1 
         0.0; 0.2
-0.1 ± 0.2 
          -0.1
Girls 
   ∆ 0 to 1 y ∆ 1 to 2 y At baseline 
         0.0 ± 0.6 
     9.8; 10.7 
—
   -1.1; 1.9
    -0.6; 0.5 
—
  126.0 ± 12.0 
 120.8; 151.8 
 134.5; 145.2 
—
   10.4 ± 23.0
    2.0; 20.0 
   -7.0; 58.0 
—
   17.7 ± 4.3
 15.8; 21.2
  15.2; 26.8 
—
      7.1 ± 1.8 
    7.0; 11.0 
   8.0; 13.5
—
      0.5 ± 0.7 
   -0.4; 1.2 
  -1.5; 1.1 
—
        7.6 ± 2.0 
    7.7; 10.3
—
—
 0.1 ± 0.3 
         0.1; 0.2 
        0.6; 1.0 
—
 5.7 ± 1.7 
         6.5; 6.9 
         7.8; 11.6 
—
1.7 ± 4.7 
         1.0; 8.0 
         0.0; 3.0 
—
0.6 ± 1.0 
        0.5; 2.3 
        0.5; 2.5 
—
 1.5 ± 0.5 
         0.5; 1.0 
        0.0; 1.0 
—
-0.3 ± 0.4 
         0.3; 0.7 
































Data are mean ± SD and range, except for n = 1 and n = 2 (data are given as individual values in range).  
Patients are divided into prepubertal (I A, prepubertal throughout the study, and I B, prepubertal at baseline), pubertal (II), and 
postpubertal (III), according to the gonadotropin-releasing hormone stimulation test response and clinical examination. 
* The change is calculated by [change in height/change in age] 





Patients are divided into prepubertal (I A, prepubertal throughout the study, and I B, prepubertal at baseline), pubertal (II), and 
postpubertal (III), according to the gonadotropin-releasing hormone stimulation test response and clinical examination. 
Data for testosterone and estradiol are median and range, except for n = 1 and n = 2 (data are individual values in range). 
Data for volumes are mean ± SD and range, except for n = 1 and n = 2 (data are individual values in range). 
A, B, C, and D indicate below detection (< 0.02nmol/L, < 0.1 nmol/L, < 0.8 nmol/L, and < 0.2 nmol/L, respectively).  
* Data are means of the volumes for left and right ovaries/ testicles; † The ovaries in one pre-pubertal girl could not be visualized; § Only 
the range is given (several levels below detection); ‡ The testicles of the other boy were not measured. 
‡ Sources: for estradiol, Hospital for Children and Adolescents, Helsinki; for ovaries and uterus, Garel et a.l286; for testosterone, 





Table 11. Development in girls and boys with familial hypercholesterolemia before pravastatin treatment and at one and two 
years.  
Before treatment   At one year Reference range‡
Estradiol mmol/L I A  0.02 (A – 0.1)               <0.09
I B   0.02; 0.03         <0.09 - 1.29
II 0.15 (0.08 – 0.42)           0.09 - 1.29
III 0.19 (0.11 – 0.88)           0.11 - 1.29
Volume of ovaries * ml I A    1.9 ± 1.6†           <1.0 - 2.3
I B 0.6; 1.1             1.2 - 4.0
II 6.1 ± 2.1             2.0 - 20.0
III     10.1             2.5 - 20.0
Length of uterus cm I A 2.9 ± 0.8             2.5 - 4.0
I B    3.3; 3.5             2.5 - 8.0
II 6.1 ± 0.9             5.0 - 8.0
III  8.4             5.0 - 8.0
   
At two years 
A (A – 0.37)  A; A 
0.03; 0.04 0.10; 0.12 
0.18 (0.1 – 0.34) 0.10 (0.10 – 0.22) 
0.29 (0.14 – 0.55) 0.11 
1.3 ± 0.2 —
1.2; 1.5 1.6
5.4 ± 1.0 6.7
3.2 —
3.0 ± 0.5 —
3.4; 3.8 3.7





Testosterone ng/mL I A B - C§ 0.3 (D - 0.4) 0.1; 0.4           0.1 - 0.9 
I B B; B         D; 0.3 0.2; 3.6           0.1 – 10.8
II       0.4; 0.5     0.7; 1.2 4.4           0.3 – 10.8 
III — — —           9.6 – 24.3
Volume of testicles *   mmmol/L I A 0.6 ± 0.4 0.7 ± 0.4 0.4; 0.9             0.5 - 4.0
I B       0.4; 0.9 0.9; 0.9 1.0‡              0.5 - 10.0
II      0.9; 1.4 1.9; 7.5   4.2             2.0 -10.0













Figure 15. Serum adrenocorticotropic hormone (ACTH) concentrations and baseline and peak 
concentrations of cortisol during ACTH stimulation test in children and adolescents with familial 
hypercholesterolemia. † Indicates that the changes in both the concentrations 0 to 12 months (30 patients) 
and 0 to 24 months (14 patients) are statistically significant (P ≤ 0.05) in ANOVA; whereas NS indicates that 
neither change was statistically significant. The reference values are those used in clinical practice at the 
Hospital for Children and Adolescents, Helsinki. 
 
The ACTH concentrations and the results from the ACTH stimulation test in HeFH patients 
appear in Figure 15. The changes in ACTH and baseline cortisol levels were statistically 
significant in ANOVA. The ACTH concentrations (range 53 – 64 ng/L) at baseline in three 
patients and at one year in one patient were slightly higher than reference (10 – 50 ng/L). 
Their basal cortisol levels were, however, normal. At two years, the ACTH concentration (9 
ng/L) in one patient was slightly lower than reference (10 – 50 ng/L), but the basal cortisol 
concentration (298 nmol/L) was normal. At one and two years, the basal cortisol 
concentrations (range 99 – 135 nmol/L) were below reference (> 150 nmol/L) in five and 
two patients, respectively. Their stimulated peak cortisol concentrations were, however, 
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The purpose of this study was to contribute to our knowledge of the pharmacokinetics, 
safety, and efficacy of pravastatin in children. In children and adolescents with HeFH, the 
pharmacokinetic profile of pravastatin was found to correspond well to that previously 
reported for adults. Side-effects were mild and typically transient, compliance was 
satisfactory, and discontinuation rates resembled those with placebo.54 In mild or moderate 
hypercholesterolemia, the cholesterol-lowering efficacy of pravastatin in general was 
sufficient, whereas in severe hypercholesterolemia, especially in the presence of 
enhanced cholesterol absorption, it was insufficient. In cardiac transplant recipients, 
plasma pravastatin concentrations were nearly ten-fold higher than those of the children 
with HeFH. Regardless of the high plasma concentrations, the short-term tolerability of 
pravastatin was good, and no serious side-effects occurred. The cholesterol-lowering 
efficacy of pravastatin was satisfactory, and 89% of the transplant recipients reached or 
maintained the target total cholesterol level of ≤ 5 mmol/L at one year of treatment. 
However, pravastatin failed to normalize the elevated serum triglyceride levels. 
Furthermore, recipients with low HDL cholesterol and a high ratio of apoB-100/apoA1 
seem to be at increased risk for the development of accelerated coronary artery disease of 
the heart transplant (TxCAD). Altogether, our results were promising, and provide a 
rationale for the early pharmaceutical intervention of hypercholesterolemia in children. 
 
 
7.1.  Pharmacokinetics of pravastatin 
Our results in the HeFH patients show that the pharmacokinetic profile of pravastatin in 
children over five years of age is similar to that previously reported in adults:290, 291 
pravastatin was absorbed rapidly, with the peak plasma concentrations (Cmax) occurring 
one-half to four hours after ingestion. The AUC and Cmax values of pravastatin in children 
corresponded well to those previously reported in adults.211, 290, 291  Another study 
describing single dose pharmacokinetics with pravastatin 20 mg in children aged eight to 
16 years is also currently available, with results similar to ours.292 The pharmacokinetics of 
other statins in children remain currently unpublished. Due to marked differences in the 
way they are metabolized,203, 205 the pharmacokinetic data of pravastatin cannot be applied 




As in adults, triple immunosuppressive medication greatly alters the pharmacokinetic 
profile of pravastatin, resulting in an approximately ten-fold increase in mean pravastatin 
plasma concentration. The exact mechanism of the interaction between pravastatin and 
cyclosporine is incompletely understood, but because cyclosporine inhibits drug 
transporters such MRP2220 and OATP1B1,221, 222 the interaction could be due to the 
inhibition of pravastatin transport.210, 223, 293 Based on our results, we suggested that the 
inhibition of MRP2 could explain the increased bioavailability of pravastatin, since the 
inhibition of the hepatic uptake of pravastatin (e.g. OATPB1B) should decrease its 
(hepatic) clearance.225 However, as the t1/2 of pravastatin in our patients failed to increase, 
the inhibition of the hepatic OATP1B1 does not seem to explain the higher Cmax and AUC 
values. Of note is that the plasma pravastatin concentrations were also high in the two 
patients treated with tacrolimus (without cyclosporine), suggesting that also tacrolimus 
could profoundly alter pravastatin pharmacokinetics. Since tacroliumus, like cyclosporine, 
is also a substrate for CYP3A4, P-glycoprotein, and OATP1B1, a similar pattern of 
interactions between tacrolimus and statins could be anticipated. However, because 
reports concerning major changes in the pharmacokinetics of statins during tacrolimus 
treatment are scarce,294 and because recent reports by Lemahieu et al. and Ichimaru et al. 
found that tacrolimus has no effect on the pharmacokinetics of atorvastatin and 
simvastatin, respectively, the potential interaction between tacrolimus and pravastatin 
warrants further study.223, 295 
 
The marked variation in pravastatin peak concentrations between individuals, 
approximately 34-fold in the HeFH group and 24-fold in the transplant recipient group, 
were noteworthy. In the HeFH group, the plasma concentrations of pravastatin were higher 
in younger and smaller patients who had received higher doses per body weight, but a 
similar correlation was absent in the cardiac transplant recipient group. Some have 
recently suspected that the polymorphism of some transporter proteins, differences in 
intragastric degradation (which for pravastatin can occur in the acidic stomach), or inter-
individual variability in small-intestinal transit could explain some of the variability.296-300 
Due to the limited number of patients, the significant inter-individual variation in the 
pharmacokinetic profiles, and the existence of a variety of these other factors, which can 
affect the pharmacokinetic results, we were unable to study in detail the developmental 
aspects of pravastatin pharmacokinetics. Larger studies are thus needed to assess the 
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potential differences related to age, gender, and pubertal development in the 
pharmacokinetics and pharmacodynamics of pravastatin in children with HeFH and in 
cardiac transplant recipients, and to assess the mechanisms underlying the inter-individual 
differences in pravastatin pharmacokinetics. Importantly, the plasma concentrations of 
pravastatin in both patient groups approximately ten hours after administration were near 
zero, indicating that pravastatin does not accumulate significantly in children administrated 
once-daily.  
 
7.2.  Efficacy of pravastatin 
 
The Finnish national Current Care (Käypä hoito) and the American National Cholesterol 
Education Program (NCEP) guidelines, as well as the International Panel on Management 
of Familial Hypercholesterolemia all recommend cholesterol-lowering dietary therapy as 
the primary treatment in HeFH children:163-165, 170 The NCEP guidelines suggest that 
dietary therapy should begin with high-risk children, such as those with HeFH, over two 
years of age. Dietary therapy has proven beneficial as early as in the first year of life,188-190 
and large, randomized controlled trials have shown cholesterol-lowering dietary therapy in 
children to be safe, providing that the caloric intake is adequate.191, 192 As with previous 
studies, the total and LDL cholesterol concentrations in the 30 children and adolescents 
with HeFH prior to treatment were considerably high, whereas the HDL cholesterol 
concentrations and triglycerides were mainly normal. The dietary intervention, consisting of 
a low-fat, reduced-saturated-fat, and low-cholesterol diet with the supplementation of plant 
stanol or sterol esters, lowered the total and LDL cholesterol levels of the subjects with 
HeFH by approximately 11% and 13%, respectively, but failed to normalize them.  
 
The clinically important therapeutic goal in HeFH patients, besides lowering total and LDL 
cholesterol levels, is to reduce the incidence of CHD and cardiovascular mortality.  
Several studies have clearly shown that adult patients with HeFH strongly benefit from 
statin therapy,11, 301-303 and that intensive statin therapy in HeFH adults and in non-FH 
patients with CHD can slow the progression of or even regress coronary atherosclerosis.11, 
31, 242, 304 However, many important questions still remain incompletely answered: At what 
age should the cholesterol-lowering therapy be initiated and to what extent can 
atherosclerotic changes be reversed? What is the optimal therapeutic regimen? What is 
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the target level of cholesterol and should it be determined individually? Are the various 
regimens cost-effective? Is the treatment safe in the long-term? Due to the paucity of 
research data, several different guidelines concerning drug therapy in HeFH patients have 
been instituted: The International Panel on Management of Familial Hypercholesterolemia 
(2004) recommends that all men over 18 years and women over 30 years with HeFH 
receive cholesterol-lowering pharmacotherapy to reduce their LDL cholesterol level to 
between 2.6 and 4.1 mmol/L, defined individually according to major risk factors (age ≥ 30 
in men and ≥ 45 in women, smoking, CHD in first-degree male relatives under 55 years or 
in first-degree female relatives under 65 years, LDL > 8.5 mol/L, HDL < 1.0 mmol/L, blood 
pressure > 140/90 mmHg, diabetes mellitus, lipoprotein a > 60 mg/dl) or clinical or 
subclinical atherosclerosis.170 However, the Panel recommends pharmacotherapy for 
children with HeFH only in the presence of major risk factors. As in HeFH, the early signs 
of enhanced atherosclerosis, such as fatty streaks, carotid artery plaques, and increased 
carotid artery intima-media thickness may develop already in the early teens without any 
clinical signs or symptoms,98-105 and because it remains unknown which changes can no 
longer sufficiently revert with therapy, many authorities currently consider drug therapy 
appropriate in children and adolescents with HeFH.43, 54, 197 The NCEP guidelines 
recommend cholesterol-lowering drug therapy to HeFH children of over ten years who, 
after dietary interventions, have 1) serum LDL cholesterol > 4.1 ml/L and a family history of 
CHD, or 2) serum LDL cholesterol > 4.9 mol/L and no family history of CHD.163, 164 The 
U.S. NCEP and the Finnish national Current Care (Käypä hoito) guidelines both 
recommend bile acid binding agents as the primary drug choice for HeFH children.163-165 
Results, however, have been modest due to poor compliance and insufficient efficacy.180, 
181, 198 Although the U.S. NCEP and the Finnish national Current Care guidelines do not 
recommend statins as the primary pharmaceuticals in this patient group, and although the 
International Panel on Management of Familial Hypercholesterolemia proposes that statin 
therapy be considered only in boys over ten years of age and in girls after puberty,170 the 
U.S. Food and Drug Administration has approved pravastatin and atorvastatin for HeFH 
children over eight and ten years of age, respectively. In our study, the HeFH patients 
were 4.9 to 18.5 years of age (mean 10.1 ± 3.4 years). Patients at this age are generally 
capable of ingesting pravastatin in tablet form. If even younger patients required treatment 
(e.g. organ transplant recipients), a pravastatin mixture would make it easier to adjust the 
doses with greater accuracy. However, no statin dose recommendations based on weight 
or body surface area currently exist. It is important to emphasize that our study did not 
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attempt to determine the right age of onset of pharmacotherapy, which clearly warrants 
further study. While the decisions concerning life-long treatment are made, the 
psychological and emotional impact of the life-long genetic disease and the premature 
morbidity and mortality it disposes the patient and affected family members should not be 
underestimated. 
 
In our children and adolescents with HeFH, pravastatin in increasing doses (maximum 10 
to 60 mg) for one to two years lowered the total and LDL cholesterol values progressively 
and statistically significantly: at 2 months by 19% and 25%, at 6 months by 23% and 29%, 
and at 12 months by 27% and 33%, respectively; this trend corresponds well to the 
efficacy profile of pravastatin reported previously for hypercholesterolemic adults with and 
without HeFH.185, 305 Because the doses were only increased if the patient had not reached 
the target total cholesterol level of 5 mmol/L, the study was not designed to determine the 
dose-response curve of pravastatin (patients with “a good response” would fall out from 
the higher doses). However, approximately 70 to 80% of the maximum efficacy was 
achieved with 10 to 20 mg. Interestingly, despite the use of high drug doses, only 
approximately one third of the patients reached the target cholesterol level of ≤ 5 mmol/L. 
In patients with a very high baseline cholesterol level, pravastatin may be insufficient, and 
other more potent cholesterol-lowering statins such as atorvastatin or rosuvastatin could 
be beneficial. Atorvastatin (10 to 20 mg) has been shown to reduce LDL cholesterol 
concentrations in HeFH children by approximately 40%.51 While the efficacy and safety of 
atorvastatin has been evaluated in children,44, 51 no data currently exist on the pediatric 
use of rosuvastatin.  
 
Since insufficiently-treated hypercholesterolemic patients with high total and LDL 
cholesterol levels are likely to remain at an increased morbidity and mortality risk of 
cardiovascular disease, determination of factors predicting the responsiveness of these 
patients to therapy would be useful. To identify such factors, we studied baseline 
cholesterol metabolism by assessment of serum non-cholesterol sterols in seven 
participants who achieved the target  level of 5 mmol/L total cholesterol by one year of 
treatment (Group A), and in nine patients who did not (Group B). Group B, with an 
insufficient response, exhibited higher baseline cholesterol concentrations and higher 
ratios of cholesterol absorption markers sitosterol and campesterol to cholesterol. 
Furthermore, high cholesterol absorption (ratio of cholestanol to cholesterol) was 
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associated with poor pravastatin response (low reduction of cholesterol at one year). This 
indicates that both the relatively weak maximum effects of pravastatin as well as the high 
intestinal cholesterol absorption of some individuals can contribute to insufficiency of 
therapy. Similar results exist for adult coronary patients receiving simvastatin among 
whom those with higher absorption and lower synthesis of cholesterol required larger 
statin doses.306 Furthermore, a recent study by Miettinen et al. showed that the risk of 
recurrence of major coronary events among a subgroup of the Simvastatin Survival Study 
(4S) patients was greater in those with higher ratio of cholestanol to cholesterol.307 This 
risk was 2.2-fold between the lowest and highest quartiles, a finding not applicable to total, 
LDL, or HDL cholesterol. 307 As in previous studies, statin therapy both in Group A and 
Group B increased the serum markers of cholesterol absorption.73 From a clinical 
viewpoint, patients with high cholesterol levels caused by the high absorption capacity 
could benefit from a combination therapy with statins and pharmaceutical agents that 
inhibit cholesterol absorption (i.e. ezetimibe). In hypercholesterolemic patients, 
determinations of cholestanol and plant sterol ratios before statin therapy could therefore 
offer an objective way to evaluate cholesterol metabolism and possibly to predict potential 
treatment-related problems. 
 
Hypercholesterolemia58, 121, 122 and hypertriglyceremia28, 125 are common concerns both in 
adult and pediatric cardiac transplant recipients; and among other factors, are thought to 
predispose to TxCAD.23, 26-28, 30, 120 TxCAD is the main cause of poor graft function and 
death among cardiac transplant recipients, and the development of effective preventive 
therapy is a considerable challenge in the treatment of transplant recipients. Early 
attempts using bile acid binding agents and fibric acid derivatives to lower cholesterol 
concentrations in transplant recipients often led to an insufficient outcome, unacceptable 
side-effects, and disturbances in cyclosporine metabolism.183, 308 The new cholesterol-
lowering agent ezetimibe which inhibits cholesterol absorption, is likewise not currently 
recommended for cardiac transplant recipients due to the lack of safety data and the 12-
fold increase in the plasma concentrations of ezetimibe following its co-administration with 
immunosuppressive medication.32 In adult cardiac transplant recipients, promising results 
have been obtained with statins, particularly with pravastatin at a daily dose of 20 to 40 
mg.33 Besides lowering the total and LDL cholesterol levels, pravastatin and simvastatin 
have been shown to reduce the incidence of TxCAD, impaired endothelial function, 
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rejection, early myocardial infarction, and death.32-37 Since accelerated TxCAD is also the 
main cause of poor long-term survival in pediatric cardiac transplant recipients,16 to assess 
the tolerability, safety and efficacy of statins in this patient group is important. However, 
limited information on the safety and efficacy of statins in pediatric cardiac transplant 
recipients is currently available, since, besides this study, only a few retrospective reports 
with pravastatin and atorvastatin have been published.55-58 
 
Surprisingly, the mean total and LDL cholesterol levels of the transplant recipients were 
quite similar to those of the healthy pediatric controls. However, in 32% and 26% of the 
recipients, the total and LDL cholesterol concentrations were higher than the target values 
of 5 mmol/L and 3 mmol/L, respectively; and in a high-risk population such as cardiac 
transplant recipients, even slightly increased cholesterol concentrations may be harmful. 
The baseline apoB-100 concentration and the apoB-100/apoA-1 ratio of the transplant 
recipients were significantly higher than those of the healthy controls. Furthermore, the 
serum HDL cholesterol concentrations of the transplant recipients were significantly 
reduced, and the triglyceride levels increased. The relationship between high serum LDL 
cholesterol concentrations and the incidence of CHD is well established in both transplant 
and non-transplant subjects. However, several studies have indicated that the level of 
apolipoprotein B-100 and the ratio of apoB-100/apoA-I are even better predictors of the 
risk of vascular disease than are LDL and HDL cholesterol, respectively.309-313 Besides 
LDL, other lipoproteins that contain apoB, such as VLDL, are also known to promote 
atherosclerosis.314 In our transplant recipients, pravastatin at an average dose of 0.3 
mg/kg, roughly corresponding to the dose of 20 mg in adults, significantly decreased the 
apoB-100 concentration and the apoB-100/apoA-1 ratio of the recipients and brought them 
closer to that of the healthy controls. After one year, pravastatin (10 mg/day) had 
significantly decreased the total and LDL cholesterol concentrations of the transplant 
recipients, with mean reductions of 10% and 19%, respectively. Of the transplant 
recipients, 89% reached or maintained the target total cholesterol concentrations. 
However, pravastatin intervention failed to normalize the elevated triglyceride levels of the 
transplant recipients; in fact a slight increase in the serum triglycerides occurred during the 
one-year follow-up. Although the role of hypertriglyceridemia in atherosclerosis has been 
under debate, recent studies and meta-analyses suggest that elevated serum triglycerides 
are an independent risk factor for atherosclerosis and CHD.314-317 It remains unclear, 
however, whether triglycerides themselves are atherogenic, or whether their elevation 
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merely reflects an increase in the concentrations of triglyceride-rich remnant lipoproteins 
known to promote atherosclerosis and increase the risk of CHD.314 Persistent 
hypertriglyceridemia can aggravate low HDL cholesterol, and the combination of high 
triglyceride and low HDL cholesterol levels is known to be a powerful risk factor for CHD 
death, even in the absence of hypercholesterolemia.315 
 
Those cardiac transplant recipients with angiographically detectable coronary 
abnormalities before pravastatin exhibited persistently lower serum HDL cholesterol 
concentrations than did those with apparently healthy coronaries. Furthermore, the apoB-
100/apoA1 ratio of the patients with TxCAD remained higher throughout the study than 
that of the patients without TxCAD, whereas no significant differences occurred in their 
total or LDL cholesterol concentrations. Moreover, high LDL cholesterol concentrations,143 
low HDL cholesterol concentrations,149-152, 318, 319 and high apoB-100/apoA-1 ratio309-313 are 
also well-known risk factors for coronary atherosclerosis. Large experimental, 
epidemiological, and clinical studies have shown that low HDL cholesterol is an 
independent risk factor for atherosclerosis and CHD regardless of the serum levels of LDL 
cholesterol and triglycerides.150, 151 Besides playing a key role in the reverse cholesterol 
transport process,60, 76, 77 HDL particles are believed to have several other anti-
inflammatory, antioxidant, antitrombotic, and antiproliferative properties.77 HDL also seems 
to protect the endothelial cells from cytotoxic damage caused by remnants of triglyceride-
enriched lipoproteins.83  
 
Corticosteroids may cause insulin resistance, hypertriglyceridemia, and elevated VLDL 
cholesterol concentrations, whereas cyclosporine can increase serum LDL cholesterol 
concentrations.123, 124 Dyslipidemias are, therefore, exceedingly common in adult and 
pediatric cardiac transplant recipients.16, 17 Besides high triglycerides and low HDL 
cholesterol, other characteristics of metabolic syndrome that commonly occur in transplant 
recipients (i.e. small, dense LDL phenotype, abdominal obesity, and insulin resistance)125 
also impair endothelial function, enhance thrombosis, and promote atherosclerosis.314 
Therapeutic life-style changes, including regular physical exercise, smoking cessation, 
weight loss, and a health-promoting diet are therefore a vital part of treatment. In adult 
transplant recipients, promising results regarding the management of hypertriglyceridemia 
have been obtained with omega-3-fatty acids confined from fish oil.183, 320 As 
hypertriglyceridemia is associated with low HDL cholesterol, omega-3-fatty acids may also 
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be of some benefit in the treatment of transplant recipients with low HDL cholesterol.183, 320 
In addition to non-pharmaceutical regimens, statins are commonly used nowadays as a 
routine post-transplantation therapy for the treatment of hypercholesterolemia. Whether all 
pediatric cardiac transplant recipients should receive statins regardless of cholesterol level 
currently remains uncertain. As in our recipients, pravastatin effectively reduces the 
elevated serum cholesterol levels, but often fails to correct the high serum triglycerides 
and low HDL cholesterol concentrations.32 Rosuvastatin, with triglyceride-lowering and 
HDL cholesterol-elevating properties more potent than pravastatin, may thus be warranted 
in recipients with markedly elevated triglycerides and constantly low HDL cholesterol.185, 
Thus far, however, only one short-term (6-weeks) study assessing the safety and efficacy 
of the combination therapy with rosuvastatin and immunosuppressive medication has been 
published in adult recipients,321 and therefore further studies are required before 
rosuvastatin therapy can be recommended for the treatment of pediatric transplant 
recipients. Fibric acid derivatives and nicotinic acid increase the HDL cholesterol 
concentrations to a greater extent than do statins.77, 322 On the other hand, the use of fibric 
acid derivatives in transplant recipients requires caution, especially if they are used 
concomitantly with statins, because of the increased risk of rhabdomyolysis.308 Due to a 
high incidence of adverse events, nicotinic acid is rarely used in transplant recipients.308 
Altogether, effective statin therapy, steroid-free immunosuppression (whenever possible), 
regular exercise, weight control and a lipid-lowering diet with omega-3-fatty acids are 
advisable in reducing the metabolic stress that predisposes cardiac transplant recipients to 
premature atherosclerosis.183, 320 
 
In adult cardiac transplant recipients, statins such as pravastatin and simvastatin have 
markedly improved both the patient and graft survival rates.32-40 Although pediatric data 
are scarce, a retrospective analysis by Mahle et al. suggested that the post-transplantation 
use of pravastatin was associated with a lower incidence of TxCAD. Of our six patients 
with TxCAD prior to pravastatin, one patient died of severe vasculopathy and another 
underwent stent a operation during the four-year follow-up, which reflects the severity of 
the disease. Since the severe coronary abnormalities in both patients had already been 
diagnosed three and one years before the initiation of pravastatin, respectively, pravastatin 
therapy was obviously started too late in order to prevent coronary vasculopathy. In the 
remaining four, the coronary changes remained unchanged, or progressed only slightly. 
Two patients (of 13) with healthy coronaries at baseline developed TxCAD during 
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pravastatin intervention after a preceding grade I rejection. Altogether, the gradual 
progression of the coronary lesions in some patients indicates that pravastatin may be 
insufficient to completely suppress TxCAD in pediatric cardiac transplant recipients. It 
should be noted, however, that in the transplant recipients, due to potential safety 
concerns, the daily doses of pravastatin were not increased from 10 mg. Due to the limited 
number of patients, differences in the initiation-time of pravastatin and the lack of a 
placebo group, larger trials with a more homogenous patient population and a longer 
follow-up period are required to determine ultimately whether and at what dose pravastatin 




7.3.  Safety of pravastatin  
While no serious side-effects of pravastatin occurred in HeFH patients, the mild side-
effects were mostly transient and occurred during the first weeks; thus they did not appear 
to be dose-dependent. In accordance with previous studies, headache and gastrointestinal 
symptoms were the most common side-effects. Of note, the same symptoms were also 
common before pravastatin. Since fat-soluble vitamins are transported in association with 
lipoproteins, cholesterol-lowering statin therapy has been feared to lead to vitamin 
deficiencies. Although a small statistically significant decrease in vitamin E levels was 
observed, the serum levels of fat-soluble vitamins remained satisfactory. Our results are 
therefore in line with those of previous studies in HeFH children, thus indicating that no 
significant reductions in fat-soluble vitamins occurred during statin therapy.43, 54 The 
changes in CK, ALT, or creatinine concentrations were not clinically relevant, and no 
marked abnormalities that would have required the discontinuation of pravastatin therapy 
(Pravachol product information) occurred. Furthermore, compliance was satisfactory. 
 
Since cholesterol plays many essential roles in growth and development,59 the lack of 
long-term safety data has restricted the use of statins in children. The first study was that 
of Sinzinger et al. in 1992.52 Currently, several studies addressing the short-term safety of 
different statins in children are available. 41, 43, 44, 46-54 Before the initiation of our study, only 
Stein et al. had launched data on the growth and pubertal development of adolescent 
males receiving lovastatin.54 In 2002, de Jongh et al. published a similar study on 
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adolescents (females and males) treated with simvastatin.47 Furthermore, after the 
completion of our study, Wiegman et al. reported the absence of adverse effects of 
pravastatin on growth and pubertal maturation in children and adolescents (8-18 years) 
during a two-year period.43 As the pravastatin doses in the latter study were 20 mg in 
children of under 14 years, and 40 mg in adolescents of over 14 years, the doses in our 
study, especially in the younger children, were considerably higher. Also, unlike previously, 
we studied the growth and development of individual patients in relation to their age, 
pubertal stage and gender. To our knowledge, no previous study has reported on the 
growth and development of young children taking any statin. Nine of our patients were 
under eight years of age, and the youngest only 4.9 years old; also, in these patients 
pravastatin was safe and well-tolerated. Importantly, pravastatin treatment did not delay 
pubertal development or cause hormonal disturbances at any age: progressions in Tanner 
staging, estradiol and testosterone levels, and gonadal volumes were normal. 
Furthermore, growth was not adversely affected. The observed slight but statistically 
significant alterations in the plasma ACTH and baseline cortisol levels were most likely of 
little clinical relevance and no patient showed signs of hypocortisolism. In previous statin 
studies in children, the changes in cortisol concentrations have been non-significant.43, 54 
Adverse effects of pravastatin or simvastatin on adrenal function were neither observed in 
adults.323-327 Even though the follow-up was among the longest of any statin study in 
children, an even longer follow-up period from early childhood to adulthood is required to 
ultimately conclude the long-term safety of pravastatin therapy in children.  
 
 
Despite the higher plasma concentrations in the cardiac transplant recipients, pravastatin 
was well-tolerated, without significant short-term side-effects. In fact, we observed none of 
the more serious side-effects, such as rhabdomyolysis or hepatotoxicity, reported more 
commonly in adult recipients.328 Overall, no clinically significant changes in glomerular 
filtration rate (determined by 51Cr EDTA clearance) or plasma creatinine, ALT, or CK 
concentrations occurred, and we observed no signs of increased cyclosporine renal 
toxicity. Although headache is a common complaint in patients on cyclosporine, its 
frequency did not increase during the two-month follow-up period. Due to marked 
polypharmacy and the use of potentially hepato- and nephrotoxic substances, careful 
follow-up of hepatic and renal functions is crucial in cardiac transplant recipients. In 
pediatric transplant recipients undergoing immunosuppressive therapy, future trials 
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assessing the safety of pravastatin at daily doses exceeding 10 mg are still warranted. 
Although pravastatin did not adversely affect growth and pubertal development in patients 
with HeFH, growth and development during the combination therapy with 
immunosuppressive medication in pediatric recipients also remains to be determined.  
 
7.4.  Study limitations  
An important limitation in our study was that, due to the relatively small number of HeFH 
patients treated at the Hospital for Children and Adolescents, Helsinki, this was an open 
clinical follow-up rather than a randomized, placebo-controlled, double-blind study. With 
the pediatric cardiac transplant recipients, the hospital’s current treatment protocol 
includes the post-transplantation use of statins. Since recipients are at a very high risk for 
TxCAD,16, 17 and since statins in adults have been shown to decrease cardiovascular 
mortality and morbidity after transplantation, 32-40 a placebo-controlled study in this patient 
group could be considered unethical. The relatively small number of participants in both 
patient groups, and especially in smaller subgroups, restricted the statistical power, and in 
some cases hindered the attainment of definite conclusions (i.e. the sufficiency of 
pravastatin for TxCAD prevention). Also, the variation in patient age, size and pubertal 
stage was considerable, which may limit the validity of the results in a given age group. 
Both children with HeFH and pediatric cardiac transplant recipients as a patient group are 
unique whereby the results from this study cannot be applied directly to all children (i.e. 
transplant recipients of other organs). Considering that the pharmaceutical intervention in 
both groups is likely to be life-long, larger trials with an even longer follow-up period are 
still warranted to confirm the promising results of our study. 
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8. SUMMARY AND CONCLUSIONS 
In order to enable the pediatric use of pravastatin, my dissertation aimed to study the 
pharmacokinetics, safety, and, efficacy of pravastatin in children with heterozygous familial 
hypercholesterolemia and in pediatric cardiac transplant recipients receiving triple 
immunosuppressive medication.  
 
The main findings of the study were as follows: 
1 The pharmacokinetic profiles of pravastatin in children with HeFH and in pediatric 
cardiac transplant recipients corresponded well to those previously reported in 
adults with HeFH and in adult transplant recipients, respectively. The peak plasma 
concentrations of pravastatin in pediatric transplant recipients were nearly ten-fold 
higher than in children with HeFH, indicating that significant interactions between 
pravastatin and immunosuppressive medication occur.  
2 In children and adolescents with HeFH, the cholesterol-lowering efficacy of 
pravastatin in slight or moderate hypercholesterolemia was satisfactory, whereas in 
severe hypercholesterolemia, especially in the presence of enhanced cholesterol 
absorption, it was insufficient. These patients with high baseline cholesterol levels 
together with high cholesterol absorption could benefit from a combination therapy 
of statins and ezetimibe, which inhibit both cholesterol synthesis and absorption, 
respectively. 
3 In pediatric cardiac transplant recipients, pravastatin lowered the serum total and 
LDL cholesterol concentrations effectively, but failed to normalize the elevated 
triglyceride levels. Low HDL cholesterol concentrations, associated with high serum 
triglyceride levels, and high serum apoB-100/apoA-1 ratios were associated with 
the development of TxCAD. Altogether, effective statin therapy, steroid-free 
immunosuppression (whenever possible), regular exercise, weight control, and a 
lipid-lowering diet with omega-3-fatty acids should be favored in order to reduce the 




4 In both groups, pravastatin was safe and well-tolerated. No serious side-effects 
occurred, and pravastatin did not increase the alanine aminotransferase, creatinine, 
or creatine kinase values to a clinically relevant extent. In children and adolescents 
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